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Currently pericytes are considered to represent mesenchymal stem cells (MSCs) in a 
perivascular niche and can be recruited from bone marrow (bm). However literature in the 
past often suggested pericytes to express hematopoietic markers, when pericytes were studied 
at early stages of angiogenesis. MSCs lack hematopoietic and monocytic markers by 
definition. Therefore the discrepancy in marker expression of pericytes pointed to the notion 
that more than one pericyte population exists. “Early” pericytes would be hematopoietic and 
support early stages of angiogenesis. “Late” pericytes would be MSCs and recruited to 
forming vessels at later stages of angiogenesis, where they would stabilize and support 
maturation of formed vessels.  
 
We generated a novel, spindle-shaped, adherent cell type from human peripheral blood, 
which expressed besides hematopoietic markers CD45 and CD11b, pericyte-related markers 
PDGFR-β, NG2 and desmin. Therefore the generated cells could resemble the hematopoietic 
pericyte population, which was only studied in vivo so far. However, pericytes are an elusive 
cell type and so far there is no established knowledge on how to identify pericytes in vitro.  
 
Therefore we studied available pericytes derived from the placenta. We used this cell type to 
establish a pericyte specific marker expression and in vitro functional profile.  
Recently pericytes were isolated systematically from various tissues and were shown to be 
MSCs. In the scientific field the question arose if all MSCs might act as pericytes. Therefore 
we compared pericytes with bmMSCs and fibroblasts. We identified markers NG2, desmin 
and Tie-2 to distinguish pericytes from other stromal cells and demonstrated that only 
pericytes enhanced sprouting and sprout integrity in a spheroid sprouting assay. Further only 
pericytes contributed to cord formation with endothelial cells (EC) in a monolayer. We 
propose that pericytes are a subpopulation of MSCs, with specialised functions in blood 
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vessel biology that are not inherent to all MSCs. Thereby we also identified markers and 
functional behaviour in vitro to identify pericytes and distinguish it from other cell types.  
 
We then subjected the adherent spindle-shaped cells derived from human peripheral blood to 
the same assays. We showed that the generated cells co-localised with and stabilised 
endothelial networks on matrigel. Further we have shown that they enhance endothelial 
sprouting in vitro. The subcutaneous co-injection of generated cells with U87 glioma cells 
resulted in larger tumours with higher vasculature density. As the generated cells behaved 
strongly pro-angiogenic in vitro and in vivo we named them blood-derived angiogenic cells 
(BDAC). The pro-angiogenic secretion profile of BDAC indicated a role of BDAC in the 
support of endothelial migration, proliferation and sprouting. MMP9, secreted by BDAC, was 
proven to be a main driver thereof.  
 
In conclusion we developed a biotechnological platform to generate functional angiogenic 
cells from peripheral blood in clinically relevant numbers. This opens avenues for generating 
patient-specific cells from an easy accessible and renewable cell source for cell-based 
treatment of ischemic diseases. Further BDAC resemble a haematopoietic pericytic 
population described only in vivo so far. Therefore this will allow a more detailed study of 
these cells and their role in angiogenesis in vitro.  
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Chapter 1: Pericytes, more than just MSCs? A functional in 
vitro study of pericytes and bone marrow MSCs in 
angiogenesis 
 
Scope of Chapter 1 
 
Pericytes are an elusive cell type. Therefore this chapter aims to better characterize pericytes 
in vitro in terms of marker expression and functional behaviour. Pericytes derived from the 
placenta were compared with other similar cell types and the established knowledge shall 
serve as a benchmark to identify pericytes in vitro and compare it to other potential pericyte 
populations and other angiogenic cells.  
Ms. Yingting Wang, a master student, who joined the project under my supervision during the 
last year helped with the conduction of some of the experiments. Together we established the 
marker profile and she performed the majority tube formation assays on matrigel. The raw 
data were analysed and compiled by myself. A manuscript that comprises of these data was 





Identification of pericytes 
 
Capillaries, arterioles and venules are small blood vessels composed of EC forming tubules 
with pericytes residing within the basement membrane of the vessels and in some spots in 
direct contact with EC (Sims 1986). Therefore pericyte identification is best done by electro-
microscopical analysis, but is often not practical or possible when referred to cells at 
angiogenic sprouts, where the basement membrane is discontinuous or to cells in vitro. In this 
case the perivascular location and a set of pericyte markers are used. Common markers for 
pericytes are platelet-derived growth factor receptor β (PDGFR-β) (Armulik et al. 2011), 
neuron-glial antigen 2 (NG2) (Ozerdem et al. 2001), α-smooth muscle actin (α-SMA) and 
desmin (Armulik et al. 2011). None of these markers selectively identifies pericytes therefore 
a set of markers is required (Armulik et al. 2011). Recently another marker CD146 was 
identified and used to isolate pericytes from various tissues (Shi et al. 2003; Li et al. 
2003; Crisan et al. 2008). Pericytes seem to be necessary for normal microvessel function and 
the growth factor platelet-derived growth factor B (PDGF-B) is implicated to have a major 
role in pericyte function (Gerhardt et al. 2003; Gaengel et al. 2009). 
 
 
Pericyte recruitment and function during development 
 
First knockouts of PDGFR-β or PDGF-B in mice showed the impact of this growth factor on 
the vasculature (Leveen et al. 1994; Soriano 1994). The knockout of PDGF-B gene was lethal 
at birth and resulted in dilated blood vessels, haemorrhages and oedema besides other effects 
like anaemia, thrombocythemia, enlarged and deformed hearts and reduced size of livers and 
kidneys (Leveen et al. 1994). Large blood vessels like the aorta were dilated (almost double 
the diameter) with a thinner layer of smooth muscle cells (SMC), the perivascular cells found 
around large blood vessels. As the number of SMC remained the same as in control groups 
the thinning of the muscular layer was thought due to the stretched vessel diameter. There 
was no sign of underdevelopment or degeneration of the blood vessels. As SMC are located 
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around blood vessels it was suggested that PDGF-B was not responsible for the recruitment or 
proliferation of SMC, but rather for the modulation of cellular functions like cellular 
contraction, which is necessary for vascular wall integrity. Interestingly, elastic membranes 
and collagen deposition seemed comparable to control groups therefore excluding the effect 
of PDGF-B on extracellular matrix (ECM) deposition (Leveen et al. 1994).  
Whereas the knockout of PDGFR-β resulted in similarities like haemorrhages, oedema under 
the skin and dilated small blood vessels like venules, there were no changes in major arteries, 
veins and the heart observed (Soriano 1994). These differences might be due to the specificity 
of PDGFR-β to PDGF-B. PDGF growth factor is a dimer made of two chains A and B. These 
chains can dimerise into AA, AB or BB. PDGFR- β can only bind the PDGF chain B, 
whereas PDGFR-α can bind both PDGF chains A and B. The binding of the PDGF chain to a 
receptor leads to the dimerisation of two receptors depending on which are the binding 
chains. Therefore PDGFR-αα binds all three isoforms of PDGF, PDGFR-αβ can bind PDGF 
AB and BB and PDGFR-ββ is specific for PDGF-BB (Soriano 1994). A knockout of the 
PDGF-B chain will therefore also eliminate the signalling of PDGF-B/PDGFR-α having 
further effects on organs like the heart (Leveen et al. 1994).  
A common factor in both knockouts was the observation of abnormal kidneys. Soriano found 
that kidneys displayed specks of blood (Soriano 1994). Glomeruli, which are the networks of 
capillaries in the kidney, lacked mesangial cells, the specialized pericytes in the kidney, 
leading to leakage of glomeruli.  
The cause of haemorrhages was then determined to be the lack of pericytes in various tissues 
like brain, lung, heart and adipose tissue in PDGF-B knockout mice (Lindahl et al. 1997). 
PDGFR-β positive cells were found in the wall of large blood vessels such as arteries, but 
were lacking around microvessels, indicating that PDGF-B was crucial for the development 
or recruitment of pericytes but not SMC. Capillaries in these knockouts were dilated and 
ruptured, a possible cause of perinatal death of the mutated mice. As the number of EC was 
increased in small blood vessels only, pericytes were concluded to regulate negatively EC 
proliferation as well as microvessel structure (Lindahl et al. 1997).  
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This notion was supported by earlier in vitro experiments, which showed that pericytes 
inhibited EC proliferation. This effect was specific for pericytes as other mesenchymal cells 
like fibroblast enhanced EC proliferation (Orlidge et al. 1987). 
In the absence of cell-cell contact PDGF-BB secreted by EC could enhance the proliferation 
on mesenchymal cells, whereas no effect was observed on EC. In contrast, when 
mesenchymal cells and EC were allowed to be in direct contact, the proliferation of both cell 
types was inhibited (Hirschi et al. 1999).  
In vivo it was demonstrated that PDGF-BB secretion was restricted to immature capillaries 
like capillary sprouts (Hellström et al. 1999). PDGF-B knockout mice lacked PDGFR-β 
expressing cells in several tissues like brain, heart, adipose, lung parenchyma, gastrointestinal 
villi and had a lesser abundance in skeletal muscle and skin. Again, no difference in the 
occurrence of PDGFR-β positive cells was found in the vascular plexus or in arteries 
confirming a PDGF-B independent recruitment of PDGFR-β expressing cells to larger 
vessels. Therefore it was proposed that PDGF-B secreted by migrating cells induces the 
proliferation and co-migration of pericytes from existing larger vessels. In fact, knockouts had 
a decrease in the proliferation of PDGFR-β and α-SMA positive cells, which correlated with 
the dilation of microvessels (Hellström et al. 1999). 
In the knock-down models of PDGF-B and PDGFR-β it became evident that pericytes did not 
affect the early stages of angiogenesis like capillary sprouting, as the number of capillaries, 
their branching points and also microvessel length appeared normal (Hellström et al. 2001). 
However, small blood vessels exhibited an abnormal morphology with endothelial processes 
into the vessel lumen and varying thickness of endothelium. The main vessel diameter was 
increased and it appeared that small blood vessels contained an increased number of EC. 
Concluding, pericytes negatively control EC proliferation, induce EC maturation and regulate 




Pericyte recruitment and function in induced angiogenesis 
 
The phenotype of vasculature in various tumours was comparable to that of PDGF-B or 
PDGFR-β deficient mice (Abramsson et al. 2002). Small blood vessels had a variable and 
mostly increased diameter and an increased permeability. The irregularity of blood vessels in 
tumours again correlated with a decrease of coverage of blood vessels by pericytes. Large 
areas of blood vessels were not covered and pericytes seem only loosely attached to blood 
vessels. As EC still expressed PDGF-BB and pericytes were recruited to tumour vessels when 
exogenously delivered it was concluded that the sparse presence of pericytes in tumors was 
due to a limited pool of pericytes (Abramsson et al. 2002).  
When pericyte recruitment was further inhibited in another tumour model, freshly formed 
vessels showed a similar morphology as during development. Vessels appeared dilated and 
leaky. It is worth to mention that existing pericytes stayed firmly attached to vessels. 
Furthermore, it was noticed that the absence of pericytes led to an increase of apoptotic cells 
in the tumour, where most apoptotic cells were EC and a reduction in tumour growth occurred 
(Song et al. 2005). 
Rajkumar and colleagues investigated pericyte recruitment in wound healing (Rajkumar et al. 
2006). In a mouse skin wound healing model imatinib mesylate was introduced, which is a 
small molecule drug and inhibit PDGFR-β. Animals treated with the drug showed a slower 
wound closure and reduced wound contractility due to the effect on myofibroblasts, which 
also express PDGFR-β. There were lesser infiltrating blood vessels in the wound and vessels 
appeared dilated. Pericyte proliferation was reduced in wounds of treated animals and the 
overall number of pericytes decreased (Rajkumar et al. 2006). 
Therefore pericytes seem not to be necessary for the initial formation of blood vessels during 
development or induced angiogenesis, although they are supportive. They lag behind and are 
recruited by endothelial sprouts, where they play a crucial part in EC survival, blood vessel 
maturation, stabilisation and homeostasis. Pericytes communicate with EC by paracrine 
factors and direct cell-cell contact (Gaengel et al. 2009; Armulik et al. 2011).  
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Origin of pericytes in induced angiogenesis 
 
It was demonstrated by several groups that pericytes could be recruited to forming blood 
vessels from surrounding tissue, potentially by proliferation and migration of pericytes from 
existing blood vessels, and also from the bone marrow: 
In the perivascular space of islet tumours, harboured by mice, only a subset of PDGFR-β 
expressing cells expressed other more mature pericyte markers like NG2, α-SMA (Song et al. 
2005). Desmin expression was not observed. However, when isolated, these cells gained the 
expression of NG2 or α-SMA during in vitro culture. When in co-culture with EC also the 
expression of desmin could be observed. Therefore it was confirmed that PDGFR-β 
expressing cells found in tumours were pericyte progenitors. When bone marrow of GFP-
positive mice was transplanted into mice harbouring the tumour, most pericyte progenitors 
were found to originate from the bone marrow (Song et al. 2005).  
Angiogenesis was also induced by inoculation with melanoma tumours or subcutaneous 
injection of VEGF in the ear of mice, with transplanted GFP-positive bone marrow (Rajantie 
et al. 2004). GFP-positive perivascular cells expressing NG2 but not α-SMA or desmin were 
observed. This indicates that the recruitment of pericyte progenitors from the bone marrow is 
not restricted to tumour-induced angiogenesis (Rajantie et al. 2004).  
When GFP positive bone marrow was transplanted into mice, which further underwent 
middle cerebral artery occlusion, two main populations originating from the bone marrow, 
infiltrated the brain (Kokovay et al. 2005). The population found in the brain parenchyma was 
of myeloid origin, expressing CD45 and CD11b and differentiated into microglia evident by 
Iba-1 expression. The second population was localised at remodeling blood vessels, was 
surrounded by laminin and expressed desmin, therefore resembling pericytes within the 
basement membrane (Kokovay et al. 2005). Kidd and co-workers did a quantitative study of 
pericyte recruitment into ovarian tumours or breast cancer tumours (Kidd et al. 2012). They 
used mice with transplanted GFP-positive bone marrow or transplanted GFP-positive adipose 
tissue. 21% of all pericytes around newly formed vessels in the tumour were bone marrow 
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derived and 58% were adipose tissue derived (Kidd et al. 2012). The current results clearly 
indicate that at least a subset of pericytes originates from the bone marrow in induced 
angiogenesis. What ratio of pericytes is recruited from the bone marrow to the angiogenic 
side will depend on the nature of the tumour or wound (Lamagna et al. 2006). 
 
Pericytes are a population of mesenchymal stem cells 
 
Bone marrow is a source of MSCs. The minimal criteria of MSCs as defined by the scientific 
community for cellular therapy is the ability of the cell to adhere to plastic, to express CD105, 
CD73, CD90 and to lack the expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, 
HLA-DR, as well as differentiate into the three mesenchymal lineages osteoblasts, adipocytes 
and chondrocytes under standard in vitro conditions (Dominici et al. 2006).  
Pericytes were long suspected to act as mesenchymal progenitors. As early as in 1990 
pericytes were isolated from bovine retina and grown to confluency (Canfield et al. 1996). 
They formed multi-layered areas, which differentiated into multicellular nodules containing 
collagen fibres and hydroxyapatite, indicators of osteoblasts (Canfield et al. 1996). When 
pericytes were isolated from bovine brain microvasculature and induced using a standard 
osteogenic protocol for MSCs, they formed colonies, which synthesised alkaline phosphatase, 
hydroxyapatite, collagen, glycosaminoglycans and most importantly osteocalcin. This 
indicated their ability to differentiate into osteoblasts (Brighton et al. 1992; Dore-Duffy et al. 
2006; Hirschi et al. 1996).  
Retinal pericytes were also able to differentiate into chondrocytes using a standard 
chondrogenic protocol for MSCs and into adipocytes using rabbit serum in vitro. When they 
were inoculated into diffusion chambers and transplanted into mice, chondrogenic and 
adipogenic differentiation became also evident in vivo (Farrington-Rock 2004).  
Crisan et al. was the first group to do a systemic analysis of MSC features in pericytes from 
various tissues (Crisan et al. 2008). They isolated CD146 expressing cells, which lacked the 
expression of CD34, CD45 and CD56 to avoid EC, leukocytes and myogenic cells, 
respectively. Cells were isolated from skeletal muscle, myocardium, placenta, pancreas, skin, 
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brain, bone marrow and white adipose tissue. The isolated pericytes made up 0.88% (muscle) 
to 14.6% (adipose) of total cells. They expressed MSC markers CD10, CD13, CD44, CD73 
and CD105 freshly after isolation and also after long-term expansion. More importantly, 
pericytes were able to differentiate into adipocytes, osteoblast and chondrocytes under 
standard MSC induction protocols, even at clonal level (Crisan et al. 2008). Therefore 
pericytes are able to fulfil the criteria, which define MSCs. It was even mentioned that 
pericytes are indistinguishable from MSCs in their morphology and phenotype, growth and 
differentiation behaviour. Therefore it was hypothesised that the perivascular locations in 
various tissues hold a reservoir of MSCs, which can be activated and recruited during wound 
repair and tissue regeneration (Peault 2012).  
Caplan (2008) discussed these findings and suggested that not all pericytes are MSCs since 
pericytes fulfil specialised functions, quite distinct from activities associated with the 
differentiation into various mesenchymal lineages. However, he hypothesised that all MSCs 
are pericytes and raised the question if pericytes contribute to tissue repair by differentiating 
into other lineages (Caplan 2008).  
Indeed, it was shown that similar to pericytes, MSCs can be isolated from various tissues and 
a systemic reservoir of MSCs in the perivascular space was suggested (da Silva Meirelles 
2006). Further pericytes were long thought to give rise to myofibroblasts, therefore being 
involved in wound healing as well as fibrosis (Schrimpf et al. 2011). In a couple of interesting 
studies the regenerative potential of exogenously introduced pericytes was shown. Crisan et 
al. (2009) revealed unpublished data in a review, which showed that pericytes isolated from 
skeletal muscle restored heart function after transplantation into mice with infracted hearts 
(Crisan et al. 2009). The same group and another one showed the myogenic potential of 
pericytes in vitro (Dellavalle et al. 2007; Crisan et al. 2008). Further both demonstrated that 
pericytes gave rise to numerous muscular fibres in the host, when transplanted into mice with 
muscular dystrophy or after muscle injury with cardiotoxin (Dellavalle et al. 2007; Crisan et 
al. 2008). It is worth to mention that the regenerative potential of endogenous pericytes was 
studied as early as in 1992, where pericytes and EC were exclusively labelled in vivo with 
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monastral blue (Diaz-Flores et al. 1992). By lifting the periosteum strip in an adult rat femur, 
without damaging the surrounding microvasculature, bone formation was induced. Pericytes 
were activated, detached from microvessels and started proliferating. After 3 to 6 days some 
of the previously labelled pericytes were found in the newly formed bone and resembled 
osteoblasts (Diaz-Flores et al. 1992). Tang et al. discovered recently that a subset of pericytes, 
which were identified by the established markers α-SMA, PDGFR-β and NG2, are a source of 
adipocytes during murine development (Tang et al. 2008). The current results strongly 
support that at least a subset of pericytes has a regenerative potential and act as MSCs that 
differentiate into other lineages to restore or replenish certain tissues. 
On the other hand MSCs are a heterogonous cell population (Horwitz et al. 2005), therefore 
the question remains if MSCs are identical to or can act as pericytes. Corselli et al. (2010) 
reviewed certain studies, which showed that there are other perivascular cells, which do not 
resemble pericytes, but can act as MSCs (Corselli et al. 2010). One year later the same group 
isolated CD34 positive cells from the tunica adventitia of arteries and veins in adipose tissue, 
which could be distinguished from EC, leukocytes and pericytes, as they lacked the 
expression of CD31, CD45 and CD146 respectively (Corselli et al. 2012). Isolated cells 
expressed MSC markers CD44, CD73, CD105 and CD90 in vitro as well as in vivo and 
differentiated into adipocytes, osteoblasts and chondrocytes. Therefore it was established that 
adventitial cells although being MSCs are anatomically and phenotypically distinct from 
pericytes. However, when treated with AugTP2, they could be induced to express pericyte 
markers PDGFR-β, CD146, α-SMA and NG2 (Corselli et al. 2012).  
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Goals	  and	  Objectives	  
 
Pericytes besides being MSCs have a specialised role in vascular biology. As MSCs on the 
other hand are a heterogeneous cell population, we asked the question if MSCs could 
substitute pericytes in their angiogenic and vascular responsibilities or if pericytes are MSCs 
with unique functions in vascular biology. As at least a proportion of pericytes is derived 
from the bone marrow, human bone marrow derived MSCs and human placenta derived 
pericytes, which are commercially available, were compared in their marker expression and 
functional behaviour in various angiogenic in vitro assays. We aimed to establish a platform 
to identify and characterise pericytes in vitro with easily accessible cell sources. By this 
means we hope to establish a standard for pericyte identification, which due to the availability 
of cells and other resources can be used by other research groups. Further we aimed to answer 






Pericytes shared tested flow cytometry marker profile with bone marrow (bm) MSCs 
 
The pericytes used in this study originated from the microvessels of the human placenta. They 
were ensured to express CD146, but not CD34 to avoid contamination with EC, when 
isolated. After culturing they were subjected to a marker expression analysis. 
 
Figure 1-1: Pericytes have a MSC-related marker profile. 
Pericytes derived from the placenta and bmMSCs were grown in triplicates in separate flasks for one 
passage until confluency and were stained for MSC, EC and hematopoietic markers and analysed via 
flow cytometry. Full graphs represent the isotype control, whereas checked graphs represent the stained 
sample. Data are presented as mean ± standard deviation. Pericytes and bmMSCs have an almost 
identical marker expression for the tested antigens. Pericytes lack the expression of CD117 (c-kit), 




Pericytes showed a strong expression of MSC markers CD105, CD73, CD90, CD29, CD166 
and CD13 and lacked the expression of haematopoietic markers like the pan-leukocyte 
marker CD45, B-cell marker CD19, monocyte or macrophage markers CD11b and HLA-DR 
(MHC II complex). They also lacked the expression of CD34, which is a marker for 
haematopoietic progenitors and EC, as well as the more specific EC markers CD144 (VE-
cadherin) and vascular endothelial growth factor receptor 2 (VEGFR-2) (Fig. 1-1). As 
expected, mesenchymal stem cells (MSCs) derived from the human bone marrow (bm) 
showed the exact same expression of these markers. BmMSCs further had a variable 
expression of CD117, which was not found with pericytes. The expression of CD146, which 
classified the purchased cells as pericytes in the first place, was slightly down-regulated to 
86% after being in culture and was found to be expressed in a similar distribution by the 
bmMSCs tested (Figure 1-1).  
IMR-90s, a foetal lung fibroblast cell line and further referred to as fibroblasts, were tested 
for the same set of markers. As fibroblasts are not MSCs, they serve as a negative control in 
this study. They showed the exact same marker profile as pericytes did (Figure 1-2).  
 
Figure 1-2: Fibroblast share pericyte and bmMSC marker profile  
Lung foetal fibroblasts were analysed for their expression of common MSC marker (CD105, CD73, 
CD90, CD29, CD166 and CD13), CD146 (used for pericyte isolation), endothelial marker (CD144 and 
VEGFR-2, CD34) and haematopoietic marker (CD34, CD45, CD19, CD11b, HLA-DR, CD117). Full 
graphs represent the isotype control, whereas checked graphs represent the stained sample. Data are 
presented as mean ± standard deviation. 
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Pericytes and bmMSCs but not fibroblasts differentiate into both mesenchymal 
lineages: osteoblasts and adipocytes 
 
Pericytes and bmMSCs and fibroblasts, as a negative control, were subjected to 
differentiation using standard induction protocols (Crisan et al. 2008) in the presence of 
macromolecules (Chen et al. 2011). 
 
Figure 1-3: Pericyte and bmMSCs show a multipotent differentiation potential, which is not 
shared by fibroblasts. 
Pericytes, bmMSCs and fibroblasts were induced using standard differentiation protocols (Crisan et 
al. 2008) in the presence of macromolecules (Chen et al. 2011) into osteoblasts or adipocytes. Fat 
droplets were stained using nile red and Ca2+ depositions were visualised with alizarin red. Only 
pericytes and bmMSCs accumulate lipid droplets (in gold), although Ca2+ was deposited by fibroblasts 
as well. Data are representatives of three independent experiments. 
 
Adipocyte differentiation was confirmed by staining for lipid droplets, which were present in 
differentiated pericytes and bmMSCs but were lacking in fibroblasts (Fig. 1-3). More 
pericytes differentiated into cells containing lipid droplets, however lipid droplets appeared 
smaller than the ones in differentiated adipocytes from bmMSC. Some cells did not produce 
lipid droplets in the bmMSCs differentiation cultures, as indicated by the stained nuclei 
without surrounding lipid droplets.  
Under conditions, which allows stem cells to differentiate into osteoblasts all three cell types 
demonstrated deposition of Ca2+, as indicated by the staining with alizarin red (Fig. 1-3). 
Induced pericytes showed the strongest deposition followed by fibroblasts. BmMSCs showed 
least deposition. Interestingly, the pattern of distribution was found to be different. 
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Differentiation of pericytes and bmMSCs into osteoblast led to the production of nodules of 
Ca2+ deposition at around three weeks, which then extended into a fibrillar pattern until it 
completely covered the cell layer in the case of induced pericytes. Fibroblasts produced 
sharp-edged stained areas at three weeks, which were also present after 4 weeks. In addition 
an even but fainter staining of the whole cell layer was observed at 4 weeks (Fig. 1-3).  
 
BmMSCs and fibroblasts do not share the expression of NG2, desmin and Tie-2 with 
pericytes 
 
Pericytes, bmMSCs and fibroblasts were explored for the expression of pericyte-related 
markers PDGFR-β, NG2, α-SMA and desmin, as well as for the expression of angiopoietin 
receptor Tie-2, using immunocytochemistry (Fig. 1-4). Pericytes expressed all of the tested 
markers. They stained brightly in a granular pattern for PDGFR-β around the nucleus and had 
a fainter expression of PDGFR-β resembling the cell shape.  
BmMSCs and fibroblasts showed an expression of PDGFR-β distributed over the whole cell 
body. However, the staining appeared weaker in both cell types than in pericytes. NG2 was 
only expressed by pericytes. The intensity of the staining of NG2 varied from sample to 
sample of pericytes. Within one sample, not all cells showed a strong expression of this 
marker. In general it was observed that the staining intensity and also the number of cells with 
a positive staining for NG2 decreased with the passage number. At the passage all further 
experiments were performed, pericytes showed expression of NG2 whereas bmMSCs and 
fibroblasts did not. The staining was found either only around the nucleus or over the whole 
cell body. An often-employed pericyte marker α-SMA was not selective for pericytes. It 
showed the strongest staining of fibres in bmMSCs. The staining in pericyte and fibroblast 
cultures had a varying intensity. Some cells showed a medium to strong staining of fibres and 
some showed a weaker stained granular pattern. Desmin was also variable for various 
samples of pericytes, but when expressed showed a fibrillar pattern. Fibroblasts and bmMSCs 





Figure 1-4: Pericyte marker NG2 and desmin are not shared by bmMSCs and fibroblast. 
Pericytes, bmMSCs and fibroblast were grown as monolayers and immunocytochemistry was 
performed for pericyte markers PDGFR-β, NG2, α-SMA and desmin as well as for the receptor Tie-2 
(red or green fluorescent staining). Nuclei were stained using DAPI (blue). Pictures were taken using 
an inverted fluorescent microscope (Olympus) at 40x magnification. Pericytes showed a selective 
expression for NG2, desmin and Tie-2. These pictures are representatives for three independent 
experiments. 
 
The angiopoietin receptor Tie-2 is a hallmark receptor in angiogenesis and expressed by EC. 
In the samples tested it was expressed by pericytes closely around the nucleus and was absent 
in bmMSC and fibroblast cultures (Fig. 1-4). 
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Co-localisation with the endothelial network on matrigel is not a pericyte-specific 
behaviour 
 
Marker expression seemed not sufficient to distinguish pericytes from other cell types. 
Therefore we employed functional in vitro assay in an attempt to identify pericyte specific 
functional behaviour. Using a tube formation assay on matrigel the question was addressed if 
co-localisation of cells with the endothelial network is a pericyte specific behaviour. Further 
we analysed the ability of cells to stabilise the formed endothelial network.  
 
Figure 1-5: Tubular network formation is endothelial cell specific.  
Endothelial cells (EC) labelled in red or pericytes, bmMSCs or fibroblasts labelled in green were 
cultured on matrigel. All pictures were taken at 12 hours. Endothelial cells form a tubular network on 
matrigel, whereas all mesenchymal cells form aggregates, which have different degrees of contractility. 
These pictures are representatives for three independent experiments. 
 
When seeded on matrigel EC formed a tubular network within the first 4 hours and remained 
over a period of two days (Fig. 1-5). During this time the network disintegrated slowly as 
evident by the appearance of single cells, which were not incorporated into the network 
anymore and tubes that contracted together to form thicker ones, until finally some of them 
resulted in round cell aggregates. Although all mesenchymal cell tested were able to rearrange 
to form a network on their own, but the network did not last long as cells had formed huge 
cell aggregates at 12 hours (Fig. 1-5). 
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Figure 1-6: Co-localisation with endothelial tubular network is not pericytic-specific. 
Endothelial cells (EC) labelled in red were cultured with pericytes (Prc), bmMSCs (MSC) or 
fibroblasts (Fb) labelled in green on matrigel at various ratios. All pictures were taken at 12 hours. 
These pictures are representatives for three independent experiments. 
 
Pericytes are known to be attached to small blood vessels. Therefore EC and mesenchymal 
cells were labelled in red and green, respectively and EC were seeded with pericytes, 
bmMSCs or fibroblast on matrigel (Fig. 1-6). All mesenchymal cells co-localised with the 
tubular network formed by EC as indicated by areas, where red and green labelling is in 
contact and by yellow areas, where EC and mesenchymal cells overlapped. They adhered 
along the tubes and concentrated at the junction points. No difference in the distribution 
pattern between the different mesenchymal cells was observed (Fig. 1-6).  
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Figure 1-7: Only pericytes maintained endothelial network. 
Endothelial cells (EC) labelled in red were cultured with pericytes (Prc), bmMSCs (MSC) or 
fibroblasts (Fb) on matrigel at various ratios. All pictures were taken at 12 hours. Only red stained EC 
are displayed. When EC are co-cultured with Prc less but thicker tubes are formed, which are stable 
overtime. MSC and Fb on the other hand collapse the network in a cell dose-dependent manner. These 
pictures are representatives for three independent experiments. 
 
At 12 hours at low EC:mesenchymal cell ratios of 2:1 and 5:1 bmMSCs and fibroblasts 
contracted the tubes into cell aggregates and the network was destroyed. At the same ratios 
pericytes did not destroy the network although less but thicker tubes formed (Fig. 1-7). With 
increasing EC:mesenchymal cell ratios 10:1 and 20:1 the contraction of tubes by bmMSCs or 
fibroblasts was reduced. However, even at high EC:mesenchymal cell ratio the destruction 
force of bmMSCs and fibroblasts was still obvious. In contrast, at high EC:pericyte ratios 
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10:1 and 20:1 less tubes with a larger diameter were formed, but the network was not 
contracted in the same manner as with bmMSCs and fibroblasts (Fig. 1-7). 
 
Figure 1-8: Only pericytes maintained endothelial network over a course of 24h.  
Endothelial cells (EC) labelled in red were cultured with pericytes (Prc), bmMSCs (MSC) or 
fibroblasts (Fb) on matrigel at EC:mesenchymal cell ratio 20:1. All pictures were taken at 24 hours. 
Only red stained EC are displayed. When EC were cultured alone tubes disintegrate over a course of 
24h. Tubules in co-cultures of EC with Prc appeared less then at 12h, however they were mostly intact. 
MSC and Fb on the other hand collapse the network into cell aggregates. These pictures are 
representatives for three independent experiments. 
 
At 24 hours the network was mostly destroyed in co-cultures with bmMSCs and fibroblasts 
even for high EC:mesenchymal cell ratio 20:1 as evident by the mainly presence of cell 
aggregates (Fig. 1-8). EC:pericyte co-cultures at ratios 20:1 were comparable in their number 
of tubes to EC monoculture controls at 24 hours. Interestingly, tubes in EC monoculture 
controls disintegrated as they consisted of thin, loose and discontinuous tubes, whereas the 
EC:pericyte co-cultures consisted of thicker and compact tubes. We did not observe any 
significant stabilisation effect of pericytes under chosen conditions of full EC growth 
medium, although EC:pericyte co-cultures showed a trend towards more consistent tubules 




Figure 1-9: Pericytes are able to significantly maintain endothelial tubular networks on matrigel.  
Endothelial cells (EC) were cultured with pericytes (Prc), bmMSCs (MSC) or fibroblasts (Fb) on 
matrigel at a ratio of 20:1 in LG DMEM containing 0.5 % FBS. Pictures of cultures were taken at 
various time points and the cumulative tube length per taken area was calculated using Fiji software. 
Results are displayed as mean value ± standard deviation. Results are representatives of three 
independent experiments. Although cultures of endothelial cells alone resulted in the highest length of 
the tubular network, this network disintegrates faster than in co-culture with pericytes. BmMSCs and 
fibroblasts destroy the network over time. 
 
In matrigel tube formation assays in starving media, endothelial cells alone were still able to 
generate a network with the highest cumulative tube length (Fig. 1-9). However the network 
disintegrated over time resulting in a lower cumulative tube length at 24 hours than in co-
cultures with pericytes at a ratio of 20:1. Therefore pericytes were able to significantly 
maintain the tubular network in comparison to the endothelial cell controls. MSCs and 
fibroblasts on the other hand destroyed the network (Fig. 1-9). 
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Pericytes contribute to endothelial sprouting 
The effects of pericytes on endothelial sprouting was analysed and compared to that of 
bmMSCs and fibroblasts, using an in vitro spheroid sprouting assay, which is a representative 
system for capillary sprouting. When endothelial cells were seeded as spheroids into a 
collagen I gel, they started budding and formed elongated processes into the gel resembling 
sprouts (Fig. 1-10). Although all mesenchymal cells tested formed spheroids, the sprouting 
behaviour was specific to EC, as pericytes, bmMSCs and fibroblasts alike migrated away 
from the core as single cells. Formations of tubular or cord-like structures, which could have 
indicated a sprout, were not observed (Fig. 1-10). 
 
 
Figure 1-10: Sprouting in an in vitro spheroid-sprouting assay is endothelial cell specific.  
Endothelial cells (EC) pre-labelled in red or pericytes (Prc), bmMSCs (MSC) or fibroblasts (Fb) pre-
labelled in green were cultured to form spheroids, which were then seeded into collagen I gels to 
sprout. EC forms sprouts, whereas mesenchymal cells migrated as single cells through the gel. These 




Figure 1-11: Pericytes enhance sprouting in an in vitro spheroid sprouting assay. 
Endothelial cells (EC) pre-labelled in red were cultured with pericytes (Prc), bmMSCs (MSC) or 
fibroblasts (Fb) at various ratios to form spheroids, which were then seeded into collagen I gels to 
sprout. Only the red stained EC are displayed. Sprouts of EC alone had irregular morphology and 
margins. 2:1 ratio of EC to Prc, MSC and Fb yielded in less sprouting (MSC>Prc>Fb), however 
sprouts showed tighter and stretched morphology with smooth margins. Sprouting at ratios 10:1 in co-
cultures exceeded that of EC alone (MSC>Prc>Fb≈EC alone). Sprouts in EC:MSC and EC:Fb co-
cultures still appeared thin, stretched out and disrupted comparable to 2:1 ratios of the respective co-
cultures. Only sprouts in EC-Prc co-cultures increased in diameter remaining a smooth, regular and 
compact morphology. These pictures are representatives for three independent experiments. 
 
To be able to distinguish EC from other mesenchymal cell types in spheroids, all cells were 
labelled before co-culture. EC (in red) were seeded with mesenchymal cells (in green) at 
different ratios. When EC were cultured alone, the core became loose and expanded while the 
sprouts formed. The sprouts were wide and had irregular shape and margins. Cells composing 
the sprouts were loosely arranged (Fig. 1-10). In contrast, in co-cultures of low endothelial to 
pericyte ratio 2:1, the core still contained a high density of cells indicating that cells are still 
tightly attached to each other (Fig. 1-11). Fewer sprouts formed. However, the developed 
sprouts appeared thinner with EC being more tightly associated with each other. They had a 
stretched and straight shape with smooth margins. When EC were cultured under the same 
conditions with bmMSCs instead, a similar morphology of sprouts was observed. Fibroblasts 
under the same conditions inhibited sprouting almost completely, although they did not 
contract the core to a tight cell mass as it was observed with pericytes and bmMSCs (Fig. 1-
11). With increasing endothelial to pericyte ratio 10:1 sprouting ability of EC was enhanced 
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and exceeded that of EC alone. Interestingly morphology of sprouts in EC-pericyte co-
cultures appeared still smooth and compact, but less thinned as in the 2:1 EC to pericyte ratio. 
When EC were cultured at a ratio 10:1 with bmMSCs or fibroblasts instead, sprouting was 
enhanced as compared to 2:1 ratios between EC and the respective mesenchymal cell type. 
However, sprouts still appeared thin and stretched under those conditions (Fig. 1-11). 
 
Figure 1-12: Only pericytes co-localise with formed sprouts.  
Endothelial cells (EC), pre-labelled in red, were cultured with pericytes (Prc), bmMSCs (MSC) or 
fibroblasts (Fb), pre-labelled in green, at various ratios to form spheroids, which were then seeded into 
collagen I gels to sprout. In all co-cultures most pericytes co-localised with sprouts (yellow areas in 
overlaid pictures) or were loosely attached to sprouts. Most MSC remained in the core region of the 
spheroid, although some migrated out of the spheroid, leading to a segregation of the cell types. 
However some were still in loose contact to EC. Fb migrated distances from core region exceeding the 
migratory distances of EC, leading also to a de-mixing of the cell types as found in EC:MSC co-
cultures (blue arrowheads). In EC-MSC and EC-Fb co-cultures endothelial cells often detached from 
existing sprouts and were bridged by MSC or Fb with remaining sprouts (white arrowheads). These 
pictures are representatives for three independent experiments. 
 
At 2:1 EC to pericyte ratio many pericytes were still in the core region of the spheroid, but 
also tightly attached to form sprouts indicated by yellow areas, where EC (in red) and 
pericytes (in green) overlapped (Fig. 1-12). Some pericytes were also loosely, surrounding the 
formed sprouts, but most of them were still in contact with EC. Almost no pericytes were 
detected to migrate larger distances away from the core, as it was observed, when pericytes 
were composing the spheroid alone (compare Fig. 1-10 and Fig. 1-12). At this cell ratio most 
bmMSCs remained in the core region or migrated out of the spheroids, not necessarily in 
contact with the sprouts (Fig. 1-12). Similarly, most fibroblast migrated randomly out of the 
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spheroid, generating a pattern similar to that observed, when spheroids were composed of 
fibroblast alone (compare Fig. 1-10 and Fig. 1-12). Therefore co-cultures of EC with 
bmMSCs and fibroblasts but not with pericytes led to a partial segregation of the cell types 
(Fig. 1-12). 
In 10:1 EC to pericyte ratio sprouts were mostly covered by tightly attached pericytes and 
therefore appeared yellow in the overlaid pictures, or appeared to be in contact with green-
labelled pericytes, which surrounded the sprouts (Fig. 1-12). In contrast in EC-bmMSC and 
EC-fibroblast co-cultures many EC had detached from the sprouts. Detached EC were only 
connected to the remains by bmMSCs or fibroblasts. Therefore these structures did not 
consist continuously of EC and rather resembled pseudo sprouts. BmMSCs as well as 
fibroblasts often migrated distances exceeding that of sprouts, again leading to a partial 
segregation of the cell types (Fig. 1-12). As differences in the quantity of sprouts were rather 
subtle when compared within one ratio of EC to mesenchymal cells, most observations are of 
qualitative nature.  
 
Pericytes contribute to the formation of cord structures in a monolayer co-culture 
 
To study the effect of pro-angiogenic drugs a co-culture assay of fibroblasts and EC is often 
engaged (Raghunath et al. 2009). In this assay fibroblasts are seeded and grown to a confluent 
layer and EC are seeded on top with growth factors or small molecules to be tested. When 
pro-angiogenic stimuli are provided, EC arrange to form cord-like structures on the fibroblast 
monolayer (Raghunath et al. 2009). To establish if pericytes and bmMSCs would behave in 
the same manner, VEGF was used in this assay as pro-angiogenic stimulus. EC were 
identified by vWF staining in red and mesenchymal cell were identified by the expression of 
α-SMA in green (Fig. 1-13), which was expressed by all mesenchymal cells tested (Fig. 1-4). 
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Figure 1-13: Cord structures of pericytes and EC formed in monolayer co-cultures.  
Row I-III: Co-cultures of pericytes (first column), bmMSCs (second column) and fibroblasts (third 
column), where EC were added to confluent monolayers of mesenchymal cells, were stained for vWF 
in red (identification of EC) and α-SMA in green (identification of mesenchymal cells). Nuclei were 
stained in blue with DAPI. BmMSCs and fibroblast acted like a supportive layer for EC, which formed 
single-cell thick cords. Only in EC:pericyte co-cultures cords of various thickness were formed, which 
interconnected to form a network (white arrows). Pericyte migrate and contribute to formed cords.  
Row IV and V: Samples of EC:pericyte co-cultures then underwent confocal microscopy. First row 
shows an overlay of all planes taken from 3 cords of large and medium and small thickness. In the last 
row the first 2 pictures show sections through single planes of the cords displayed above. The last 
picture in this row shows an overlay of planes taken of a one-cell thick cord. Pericytes and EC bodies 
were aligned parallel to cord direction. α-SMA fibres were more pronounced in pericytes contributing 
to cords and were align in the same direction. These pictures are representatives for three independent 
experiments. 
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As expected, EC formed cord-like structures on fibroblast monolayers (Fig. 1-13 II and III). 
A similar pattern was observed on bmMSCs monolayers, although EC appeared to be less 
stretched out in the bmMSCs-EC co-culture. Cords appeared to consist of single EC arranged 
to form elongated processes parallel to bmMSC and fibroblast alignment. The cords were not 
interconnected in both co-cultures. α-SMA expression was stronger in bmMSCs than 
fibroblasts and seemed evenly distributed over the whole culture. Fibroblasts increased the 
expression of α-SMA around the EC cords (Fig 1-13 III). However, as evident by the 
distribution of nuclei stained with DAPI, fibroblasts and bmMSCs appeared evenly 
distributed as well (Fig. 1-13 I). In contrast EC formed cord-structures of various thicknesses 
on pericyte monolayers (Fig 1-13 II and III). The cords were interconnected and therefore 
formed a network (Fig. 1-13 II white arrows). Pericytes, which formed a confluent monolayer 
before the addition of EC, migrated towards the formed cords leaving open spaces, which 
were not covered by cells anymore. This was evident by the lack of α-SMA and DAPI in 
these areas (Fig. 1-13 I and III). Using confocal microscopy formed cords in EC:pericyte co-
cultures were further analysed (Fig 1-13 IV and V). Cords of various thicknesses consisted 
not only of EC as in the EC:bmMSCs and EC:fibroblast co-cultures, but had pericytes 
incorporated. Both cell types intermingled in larger cords as EC and pericytes were found in 
one plane of the cord. This was demonstrated in sections through single planes. At smaller 
cords, mainly consisting of the alignment of single EC, pericytes were found to be covering 
the bottom and EC resided on top of pericytes. In these cords the structure of single cells 
could be observed. EC and pericyte cell bodies were stretched out along the direction of the 
cord. Interestingly, intracellular fibril staining for α-SMA was pronounced in pericytes 
incorporated into cords and even these α-SMA fibrils were aligned parallel to the cord 
direction. In contrast pericytes, which had not incorporated into a cord often showed a weaker 





Pericytes were originally described to be indistinguishable in culture from MSCs (Peault 
2012). Consistently, the placenta-derived pericytes showed a highly similar marker profile to 
that of bmMSCs. More importantly they expressed all MSC markers they were tested for and 
lacked endothelial and haematopoietic markers, as expected for MSCs (Dominici et al. 2006). 
However the fibroblasts, which served as a negative control, expressed the same marker 
profile, indicating that marker expression is not sufficient to identify pericytes as MSCs. 
Interestingly, CD146 the marker chosen to isolate pericytes from various tissues (Crisan et al. 
2008) was expressed by bmMSCs and fibroblasts as well and might not be selective for 
pericytes after in vitro expansion. However, the fibroblasts tested are a foetal cell line and 
thus their marker expression might not resemble the profile of primary fibroblasts.  
Therefore all cell types were further subjected to the differentiation into other mesenchymal 
lineages to test their multipotential. As expected, only pericytes and bmMSCs differentiated 
into both mesenchymal lineages: adipocytes and osteoblasts. The ability of fibroblasts to 
deposit Ca2+ under standard induction conditions is well known and might not resemble their 
ability to differentiate into osteoblasts, but rather point to their implication in pathological 
vascular calcification (Guzman 2007).  
It is well known that there are no markers selective for pericytes (Armulik et al. 
2011; Gaengel et al. 2009). To find out if pericytes could be distinguished from other MSCs 
by characteristics described for pericytes, all three mesenchymal cell types were tested for a 
range of commonly used pericyte markers. All three cell types shared indeed α-SMA and 
PDGFR-β with α-SMA strongest expressed in bmMSCs. As fibroblasts expressed these 
markers as well they could not be identified as specific pericytic markers of multipotent cells. 
NG2 and desmin on the other hand were only expressed by pericytes and are therefore valid 
markers to distinguish pericytes from other stromal cell types. However, it is shown that 
expression of these markers by pericytes is variable and depends on tissue and location of 
pericytes (Armulik et al. 2011). Another marker that was found only to be expressed by 
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pericytes but not other mesenchymal cells tested was the angiopoietin (Ang) receptor Tie-2. 
De Palma and colleagues described the expression of Tie-2 on pericytes (De Palma et al. 
2005). Ang-Tie-2 signalling was found crucial for EC-pericyte communication. Tie-2 knock-
outs resulted in the lack of pericytes and a similar defect in phenotype of microvasculature as 
in PDGFR-β knock-outs (Gaengel et al. 2009; Patan 1998). 
Once we had established the differences in marker expression, we asked if marker expression 
could be correlated with functionality in an angiogenic context. To our knowledge, so far no 
in vitro assay was described, which was able to identify pericytes by their angiogenic 
behaviour and distinguish it from other mesenchymal cells. Most common the co-localisation 
of cells with the tubular network formed by EC on matrigel was employed to show pericytic 
behaviour (Song et al. 2005; Darland et al. 2001; Dar et al. 2012). Surprisingly the behaviour 
of co-localisation was not restricted to pericytes or even multipotent cells, but all 
mesenchymal cell types tested were able to do so. The main difference between EC-pericyte 
and EC-bmMSCs or EC-fibroblast co-cultures on matrigel was the significant maintenance of 
the tubular network with pericytes, whereas bmMSCs and fibroblast collapsed the network in 
a cell dose-dependent manner. As this assay is highly dependent on the ratio of the cell types 
used and varies with the matrigel batch, proper cell controls are required to indicate a 
pericytic phenotype. 
Pericytes were shown not to be necessary for the initial formation of vasculature during 
development (Hellström et al. 2001). However, during induced angiogenesis in tumours 
(Abramsson et al. 2002; Song et al. 2005) and wound healing (Rajkumar et al. 2006) it was 
demonstrated that pericyte recruitment is supportive for new blood vessel formation. 
Accordingly, given the right EC:pericyte ratio, only pericytes were able to improve the 
integrity of the sprouts in vitro. In addition they co-localised with formed sprouts in all 
EC:pericyte ratios, as expected from pericytes. In contrast bmMSCs and fibroblast migrated 
larger distances away from EC, which led to a segregation of the cell types. Sprouts formed in 
these co-cultures often disintegrated, leading to pseudo sprouts, which did not continuously 
consist of EC, but of bmMSCs or fibroblast bridging gaps between single EC. Therefore, 
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although bmMSCs and fibroblast seem to be supportive to some extent, only pericytes 
interact with EC to enhance angiogenesis in vitro and to have a fixed position at formed 
sprouts. 
It is well established that EC, when seeded on confluent monolayers of fibroblasts and given 
an angiogenic stimulus, form cord-like structures (Raghunath et al. 2009). Again bmMSCs 
behaved in the same manner, so that both mesenchymal cell types served as a passive 
supportive layer for EC. In contrast, pericytes actively contributed to the formation of cord-
like structures of various thicknesses, which were further interconnected to form a network. 
More precisely, pericytes and EC interacted in such manner that both cell types not only 
constituted the cords, but were aligned along the cord direction. Even the intracellular α-SMA 
fibres, strongest expressed in pericytes within the cords, were aligned parallel to the cord 




Although all three cell types are derived from different tissues (placenta, bone marrow and 
lung), MSCs and fibroblasts behave alike in all angiogenic assays. Further, when pericyte-
related markers were expressed by these cells, always both MSCs and fibroblasts expressed 
these markers. Only pericytes showed a distinct expression of some of the pericyte-related 
markers and a functional behaviour in the angiogenic assays in vitro, which is related to the 
observations described in vivo. This strongly suggests that the described behaviour is due to 
the phenotype of the tested cells and not due to their tissue of origin. However such a 
statement will need further confirmation by comparing pericytes and non-pericytic MSCs 
isolated from the same tissue samples. 
It was confirmed that pericytes act as multipotent cells and therefore might play a role in 
tissue regeneration in vivo by differentiating into other mesenchymal lineages. However, the 
hypothesis that all MSCs are pericytes is refuted. MSCs as well as non-multipotent cells like 
fibroblasts behave alike and both lack the ability to interact with EC like pericytes do. Our 
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data strongly suggests that pericytes represent a subpopulation of MSCs with specialised 
functions in vascular biology that are not shared by other MSCs. These functions manifest as 
active interactions with EC to support angiogenesis, vessel integrity and are obviously not an 
intrinsic ability of all multipotent stromal cells. This has implications in the use of MSCs in 
therapeutically induced angiogenesis. MSCs are indeed a heterogeneous cell population with 
different abilities to induce angiogenesis, to stabilise formed endothelial tubules and to act as 
pericytes. 
Further, we have identified a novel set of markers and functional assays that allows 
distinction of pericytes from other stromal cells. Here we propose to use NG2, desmin and 
Tie-2 as markers to indicate a pericyte, although the expression of these markers is not 
sufficient for identification. For this purpose a combination of functional assays needs to be 
performed. Pericytes can be better identified in vitro by their ability to maintain endothelial 
networks on matrigel, their ability to qualitatively improve the integrity of sprouts in a 
spheroid formation assay, as well as their ability to migrate and contribute to formed sprouts 
in a cord formation assay. Proper cell controls need to be used in these assays and we propose 
to use the commercially available cell types employed in this study.  
In general, the assays developed represent a platform to better capture the functional 
differences between pericytes and other mesenchymal cells.  
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Materials and Methods 
Cell culture 
 
Placenta-derived pericytes were purchased from Promocell and cultured in PGM, which was 
provided by Promocell as well. Human bmMSC were purchased from Lonza and cultured in 
LG DMEM supplemented with 10% FBS and 1% Penicillin and Streptomycin (P/S). IMR-90 
are a fetal lung fibroblast cell line, which was grown in HG DMEM supplemented with 10% 
FBS and 1% P/S. Human umbilical cord EC (HUVEC) were purchased from Lonza as well 
and cultured in EGM-2 (Lonza). Cells were grown to 80-90% confluency at 37°C with 5% 
CO2 and subcultured using trypsin. Pericytes and bmMSC were used at passages p3 to p6, 




Cells were harvested and resuspended in flow cytometry buffer (FC-buffer), which contained 
PBS with 1% FBS. Cell concentration was adjusted to 100,000 to 200,000 cells in 50 µl. 
Antibodies were added to cell suspensions in volumes indicated in Table 1-1. An incubation 
of 1hour in the dark at 4°C followed. 500 µl of FC-buffer was added to cell suspension and 
cells were centrifuged at 200g for 5 minutes. Cell pellets were resuspended in 500 µl of PBS 
containing 1% of formaldehyde and stored at 4°C until analysis using flow cytometer (Cyan 
ADP flow cytometer, Beckman Coulter). 
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Antigen Cat No. Isotype Volume per 50µL Source 
Control 
Iso FITC  555573 FITC Mouse IgG2a κ 10 µl BD Pharmigen 
Iso FITC 555748 FITC Mouse IgG1 κ 10 µl   BD Pharmigen 
Iso PE 555574 PE Mouse IgG2a κ 10 µl  BD Pharmigen 
Iso PE 555749 PE Mouse IgG1 κ 10 µl BD Pharmigen 
Iso PE (CD105 only) 12-4714 PE Mouse IgG1 κ 10 µl or 5 µl e-Bioscience 
CD90 (Thy-1) 555595 FITC Mouse IgG1 κ 2.5 µl BD Pharmigen 
CD29  555443 PE Mouse IgG1 κ 2.5 µl BD Pharmigen 
CD105 (Endoglin) 12-1057 PE Mouse IgG1 κ 10 µl e-Bioscience 
CD146 (S-endo 1) 550315  PE Mouse IgG1 κ 10 µl BD Pharmigen 
VEGFR-2 (Flk-1) 560494 PE Mouse IgG1 κ 10 µl BD Pharmigen 
CD144 (VE-cadherin)  560411 FITC Mouse IgG1 κ 10 µl BD Pharmigen 
CD45  555482 FITC Mouse IgG1 κ 10 µl BD Pharmingen 
CD13 (APN) 560998 PE Mouse IgG1, κ 10 µl  BD Pharmingen 
CD34 130081002 PE Mouse IgG2a, κ 10 µl Miltenyi Biotec 
CD34 555821 FITC Mouse IgG1, κ 10 µl  BD Pharmingen 
CD73 (5’ –NT) 550257 PE Mouse IgG1, κ 10 µl  BD Pharmingen 
CD166 (ALCAM) 559263 PE Mouse IgG1, κ 10 µl  BD Pharmingen 
CD14 555397 FITC Mouse IgG2a, κ 10 µl BD Bioscience 
CD11b 347557 PE Mouse IgG2a, κ 10 µl BD Bioscience 
CD19 555412 FITC Mouse IgG1, κ 10 µl  BD Pharmingen 
CD83 556910 FITC Mouse IgG1 κ 10 µl   BD Pharmingen 
HLA-DR 556643 FITC Mouse IgG2a, κ 10 µl BD Pharmingen 
CD133/1(Prominin-1) 130090801 PE Mouse IgG1 κ 2.5 µL 5 µl Miltenyi Biotec 
CD117 (c-kit) 340529 PE Mouse IgG1 κ 10 µl BD Bioscience 




Cells were grown in 24 well-plate wells to confluency. Cells were fixed using ice-cold 100% 
methanol for 10 minutes at -20°C, methanol was removed and wells were air-dried, sealed 
with parafilm and stored at 4°C. For staining, plates were allowed to come to room 
temperature and 3% BSA in PBS was added to the wells to block non-specific binding of 
antibodies in the further steps. After 1 hour of blocking PBS containing antibodies at dilutions 
as indicated in table 1-2 were added to the wells and incubated for 1.5 hours. Wells were 
washed 3 times with PBS for 5 minutes each and PBS containing secondary antibody at 
dilutions as indicated in table 1-2 and DAPI (4',6-diamidino-2-phenylindole) at a 
concentration of 0.5µg/ml was added. After 30 minutes of incubation wells were washed 
again 3 times with PBS for 5 minutes and stored at 4°C until viewing under an 
epifluorescence microscope (Olympus, IX71) or an Apotome (Zeiss,) or confocal laser-
scanning microscope (Olympus).  
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Antigen Cat No.  Format Dilution Source 
Primary Antibodies 
PDGFR-β  ab32570 Rabbit monoclonal 1:100 Abcam 
NG2 ab5320 Rabbit polyclonal 1:100 Millipore 
α –SMA M0851 Mouse monoclonal 1:100 Dako Cytomation 
Desmin ab6322 Mouse monoclonal 1:100 Abcam 
TIE-2 sc-324 Rabbit polyclonal  Santa Cruz 
Secondary Antibodies 
488 chicken anti rabbit A21441  1:400 Invitrogen 
594 chicken anti rabbit A21468  1:400 Invitrogen 
488 chicken anti mouse A21200  1:400 Invitrogen 
594 goat anti mouse A11020  1:400 Invitrogen 
Table 1-2: Antibodies used for immunocytochemistry 
 
 
Differentiation into adipocytes and osteoblasts 
 
Cells were seeded into 24 well-plate at a cell density of 5,000 cells per well for osteogenic 
differentiation and 60,000 cells per well for adipogenic differentiation in LG DMEM 
containing 10% FBS and 1% P/S. Cells were allowed to adhere over night and were induced 
on the next day. All induction media contained a cocktail of ficoll macromolecules (Fc70 
37.5mg/ml and Fc400 25mg/ml) to enhance differentiation as described in Chen and 
colleagues (Chen et al. 2011). For osteoblast differentiation, media composed of HG DMEM 
containing 10% FBS and 1% P/S with dexamethasone (1 x 10-7 M), Ascorbic acid at 100 µM 
and β-glycerophosphate at 10 mM, was prepared freshly every time. Media was changed 
every 3 to 4 days for 4 weeks. Cells were washed 2 times with PBS, fixed using 4% 
formaldehyde and washed 2 more times with PBS. Deposited hydroxyapatite was stained 
using 40 mM alizarin red. Wells were washed 3 times with water and air-dried. For adipocyte 
differentiation induction media was composed HG DMEM containing 10% FBS and 1% P/S 
with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1µM dexamethasone, 0.2 mM 
indomethacin and 10 µg/ml insulin and the maintenance media of HG DMEM 10% FBS and 
1% P/S and 10 µg/ml insulin. Cells were induced for 4 days and then kept in maintenance 
media for 3 days. After 3-4 cycles of induction cells were washed 2 times with PBS, fixed 
using 4% formaldehyde and washed 2 more times with PBS. Lipid droplets were stained with 
lipophilic nile red ﬂuorescent dye (0.05 mg/ml in water) and DAPI (0.5 µg/ml) for 1 hour. 
Wells were washed 3 times with PBS and stored in PBS. Cells were viewed with an 
epifluorescence microscope (Olympus, IX71). 
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Life cell labelling 
 
Cells were harvested and resuspended in HBSS for cell counting. The needed number of cells 
was centrifuged down at 200g, 5 min and then resuspended in fluorescent diluent (Sigma 
PKH67/PKH26) at 500,000 cells per 100 µl. Fluorescent cocktail with 0.5 µl of florescent 
cell linker dye (Sigma PKH67/PKH26) per 100 µl diluent was prepared and mixed with the 
cell suspension at 1:1 (v/v). The samples were incubated at room temperature for 4 min and 
then 2 ml of heat-inactivated FBS (HI FBS) were added per sample to stop the reaction. The 
samples were transferred to clean test tubes and centrifuged at 200g, 5 min and supernatant 
was discarded. The pellets were washed with HI FBS 2 more times and resuspended in 
required media for further experiments. 
 
Tube formation assay on matrigel 
 
48 well-plate wells were coated with 150-200 µl of matrigel (Becton and Dickinson, Franklin 
Lakes, NJ USA). Matrigel was allowed to settle over night at 4 °C to allow an even 
distribution. On the next day whole plate was placed into the incubator at 37°C to allow the 
matrigel to solidify. HUVEC were collected and seeded in 250 µl EGM-2 with 30,000 cells 
per well. Other cell types were added at stated ratios.  
 
Spheroid sprouting assay 
 
Cells were collected and resuspended and co-seeded in EGM-2 containing 2.5 µg/ml 
methylcellulose. 500 HUVEC per well were seeded into non-adherent round-bottom 96-well 
plates overnight to form spheroids. When indicated other cell types were added at the 
mentioned ratio. 24 Spheroids were collected on the next day and resuspended in 0.75 ml of 
EGM-2 containing 5 µg/ml methylcellulose. 8 parts of collagen I solution (2mg/ml in 0.01 M 
HCl) were neutralised on ice with 1 part of 10x PBS and 1 part of 1M NaOH. Neutralised 
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collagen I solution was mixed 1:1 with spheroid suspension and 1.5 ml of the mixture were 
gently added to 12 well plate. Solutions were allowed to solidify for 2 hours at 37°C with 5% 
CO2 before 0.7 ml of EGM-2 was added on top of collagen I gels. Spheroids were allowed to 
sprout for 2-3 days and pictures were taken with an epifluorescence microscope (Olympus, 
IX71).  
 
2D cord formation assay 
 
For monolayer co-cultures pericytes, bmMSCs or fibroblast were seeded at 25,000 to 30,000 
cells per cm2 and grown to confluency for 4 days in DMEM/10%FBS/antibiotics. HUVEC 
were seeded at a ratio of HUVEC to pericytes of 1:5 on top and cultured in EBM-2 containing 
0.5% FBS with 5 ng/ml of VEGF for further 3 days. Co-cultures were immunostained for 
vWF and α-SMA and were viewed using an Apotome (Zeiss) and confocal laser-scanning 




Obtained values were averaged and are displayed as average value +/- standard deviation. P-
values were calculated using student’s t-test.  
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Chapter 2: Blood-derived angiogenic cells (BDAC) represent 
a pericytic population and enhance early stages of 
angiogenesis. 
 
Scope of chapter 2 
 
This chapter aims to characterise a novel cell type, which was derived during this PhD project 
and named blood derived angiogenic cells (BDAC). The marker profile and functional 
behaviour were established in accordance to the benchmarks we defined for pericytes in 
chapter 1. We compared BDAC to other cell types described in vivo and to other blood-
derived cell types. It was shown that these cells are strongly pro-angiogenic in vitro and in 
vivo and their mode of action was established. The current results strongly suggest that 
BDAC are a haematopoietic pericyte population, which was observed in early stages of 
angiogenesis so far only in vivo.  
Together with Ms. Yingting Wang the marker profile for this cell type was established. Ms. 
Maria Koch, an international student from the University of Applied Sciences in Bremen, 
performed in the scope of an internship the comparison of BDAC with M1 and M2 






Not all pericytes are MSCs 
 
Although there is much evidence that pericytes are MSCs, during early angiogenesis pericytes 
were described to express haematopoietic markers. MSCs do not express these markers by 
definition (Dominici et al. 2006). When angiogenesis was induced by injection of VEGF into 
mouse ears, which had GFP+ bone marrow transplanted, the majority of periendothelial cells 
were shown to originate from the bone marrow and express NG2, CD45 and/or CD11b 
(Rajantie et al. 2004). Pericytes were identified by the expression of NG2, as at this early 
stage no perivascular cells, positive for α-SMA or desmin, could be found. Although not 
spelled out in the main text results showed an overlap in the staining of NG2-CD45 and NG2-
CD11b (Rajantie et al. 2004). In another study through injection of bFGF vascularisation was 
induced in the cornea of mice, which were irradiated and transplanted with GFP+ bone 
marrow beforehand (Ozerdem 2005). During vessel formation pericytes were identified in the 
perivascular space by their expression of PDGFR-β and NG2. Interestingly, the majority of 
these cells co-expressed pan-leukocyte marker CD45 and monocyte/macrophage marker 
CD11b (Ozerdem 2005). Song et al. (2005) found that a proportion of PDGFR-β expressing 
pericyte progenitors co-expressed CD11b (Song et al. 2005). Subsequently it was proposed in 
a review by Lamagna and colleagues that pericyte were not only derived from the bone 
marrow, but also had a haematopoietic origin (Lamagna et al. 2006).  
Using an in vivo matrigel plug supplemented with a strong angiogenic stimulus namely bFGF, 
Tigges and colleagues were able to monitor infiltrating cells in various stages of angiogenesis 
(Tigges et al. 2008). They found that as early as 5 days after implantation of the plug a 
network was formed within, surprisingly in the absence of CD31+ EC. At this stage, the 
network was not perfused. Most of these cells were NG2 positive and therefore identified as 
pericytes. Interestingly, a high proportion of cells co-expressed haematopoietic progenitor 
marker CD34 and Sca-1 through various stages of angiogenesis. Intrigued by this finding they 
further examined the matrigel plug sections for macrophage marker F4/80 and pan-leukocyte 
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marker CD45. They found that majority of the NG2 expressing cells were bone marrow 
derived and co-expressed CD45. A quarter of these cells were also identified to be positive 
for F4/80. All this cells were found in the perivascular space. Macrophages (F4/80+), which 
did not express NG2, were also present within the plug, but were not found at pericyte 
locations. At a later stage of angiogenesis (after 9 days) EC formed vessel-like structures. At 
this point of time, structures were already perfused. It was observed that after a perfused 
network was formed, cells co-expressing NG2 and F4/80 were down-regulated to 10% and 
most NG2 positive cells were reported to have lost CD45 (Tigges et al. 2008). Again the co-
expression of pericyte and haematopoietic markers is in accordance to previous findings.  
 
Formulation of hypothesis 
 
Seen from today’s point of view, how can the discrepancy of pericytes being MSCs, but also 
having a haematopoietic origin be explained? One of the obvious differences in the 
experimental set-ups, which may lead to the differences in the findings, were that MSC-like 
pericytes were found and isolated from mature tissues, whereas “haematopoietic” pericytes 
were found in early stages of angiogenesis. Accordingly, Tigges et al. (2008) reported that 
pericytes found at later stages of angiogenesis, where blood vessels had formed already, had 
down-regulated haematopoietic markers (Tigges et al. 2008). As both reported cell population 
can be identified as pericytes by the mixture of pericyte markers and perivascular location (as 
suggested by Armulik et al. (2011), this prompted us to the hypothesis that more than one 
pericyte population exists. In this case pericytes of haematopoietic or more specifically of 
monocytic origin, would be found at places of newly induced angiogenesis and support early 
vessel sprouting (namely “early pericytes”) and MSC-like pericytes would enter at later 
stages of angiogenesis and induce vessel maturation and stabilisation (Fig. 7). Further, late 
pericytes are present and ensure proper blood vessel function beyond angiogenesis, at which 




Illustration 2-1: Illustration of working hypothesis.  
At least two different pericyte populations exist. Early pericytes have a monocytic origin and support 
early stages of angiogenesis, whereas late pericytes are a subset of MSCs, which are present on mature 
vessels.Late pericytes induce vessel maturation and stabilisation and at later stages of angiogenesis. 
 
 
Monocytes/macrophages during angiogenesis 
 
What are macrophages? 
 
Macrophages are highly heterogeneous cells present in almost all tissues, fulfilling highly 
specific functions there (Mosser et al. 2008). Most famous are the osteoclasts in the bone, the 
microglial cells in the central nervous system and the kupffer cells in the liver as well as 
histiocytes in connective tissue. Macrophages are derived from monocytes, which are present 
in the blood circulation and only upon entry into tissue, they differentiate into tissue-specific 
macrophages depending on the stimuli. Monocytes are derived from the haematopoietic stem 
cells in the bone marrow, which differentiate into myeloid progenitors before they enter the 
blood stream as monocytes (Mosser et al. 2008). In an attempt to classify the heterogeneity of 
macrophages a linear scale was proposed with two extrema M1 and M2 (Mosser et al. 2008). 
M1 are classically activated macrophages, which are induced by IFN-γ and TNF and secrete 
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high levels of pro-inflammatory cytokines, are microbicidal and tumouricidal and therefore 
support the resistance against infections. M2 are alternatively activated macrophages and the 
definition of M2 was expanded to all macrophages, which are not M1. Therefore the term M2 
encompasses a variety of macrophages, which differ dramatically in their biochemical and 
physiological phenotypes. In general, M2 have a decreased ability to present antigens to T-
cells and secrete minimal amount of pro-inflammatory cytokines and even suppress the 
immune response (Mosser et al. 2008). Two better defined M2 phenotypes are the wound 
healing macrophage, which support wound healing as the name indicates, and the regulatory 
macrophages, which secrete high levels of IL-10 and thereby dampen the immune response 
and limit inflammation (Mosser et al. 2008). In vitro macrophages can be induced into a M1 
phenotype by IFN- γ and TLR-ligands and are detected for their high levels of pro-
inflammatory cytokines (Mantovani 2006). The M2 phenotype can be stimulated by IL-4 and 
IL-13 and detected by the expression of mannose receptors and low levels of pro-
inflammatory cytokines and increased IL-10 levels (Mantovani 2006).  
 
Macrophage in the initial formation of vasculature during development 
 
Macrophages are detected already in early stages of the embryo (Nucera et al. 2011). First 
macrophages, which are found in the yolk sac of the embryo, are of maternal origin. Later 
macrophages are of embryonic origin. Embryonic macrophages show a M2 phenotype with 
enriched mRNA of genes associated with wound healing and angiogenesis. They also exhibit 
gene expression of the mannose receptor 1 (CD206) (Nucera et al. 2011). This emphasises the 
role of macrophages in development exceeding functions in the immune response.  
In an attempt to analyse the involvement of macrophages in the development of the 
vasculature, macrophages were observed during the vascularisation of the hindbrain in the 
murine embryo (Fantin et al. 2010). It was observed that early macrophages migrate from the 
yolk sac into the embryo proper before the vascularisation is established. During the 
formation of the vascular network these macrophages were observed to be in contact with 
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endothelial tip cells and often bridged the space between two tip cells. Cell count of 
endothelial tip cells and macrophages revealed a ratio of 2:1 indicating that macrophages 
might direct vessel fusion, which is also called anastomosis. Interestingly, macrophages were 
not only present during vessel fusion, but remained in contact with fused vessels. In order to 
find out if macrophages are crucial for vascular development, brain vasculature of 
macrophages-deficient embryos (PU.1 -/-) was analysed. A similar number of vascular sprouts 
were observed, however the vasculature showed less intersections, confirming that 
macrophages play a crucial role in anastomosis. The same involvement of macrophages was 
demonstrated postnatal in the mouse retina, which is first vascularised three weeks after birth. 
This confirmed that macrophages play a role in angiogenesis, exceeding the formation of 
vasculature in the embryo. Again the infiltration of macrophages was observed before the 
establishment of the vasculature with these macrophages bridging fusing blood vessels 
(Fantin et al. 2010). 
These observations were confirmed by Rymo et al. (2011), who repeated the in vivo studies in 
the developing retina (Rymo et al. 2011). He found that microglia, the tissue specific 
macrophages (F4/80 and Iba 1 positive) in the central nervous system, were associated with 
fusing and fused vessels in a ratio of endothelial tip cells to microglia of 2:1. A homozygous 
mouse strain with an inactive mutation in the CSF-1 gene, which codes for the receptor of M-
CSF and therefore is crucial for macrophage development, was employed. It was shown that 
mice lacked microglia in the retina one week after postnatal. Therefore this time-point was 
chosen to study the vascular formation (Rymo et al. 2011). In accordance with previous 
findings with PU.1-/- mice (Fantin et al. 2010) the vascular network appeared much sparser 
(Rymo et al. 2011). Although the total number of tip cells remained the same between 
mutants and wild-type mice, the number of filopodia-bearing sprouts was decreased. To better 
understand the mode of action of the pro-angiogenic effect of microglia, the sprouting from 
aortic rings in the presence of microglia was studied in vitro. It was observed that sprouts 
appeared earlier and more sprouts developed in the presence of microglia. Although microglia 
migrated to the sprouts, the sprouting was enhanced before a physical contact between 
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microglia and the sprouts was established. It was concluded that besides the physical contact-
mediated support during anastomosis, in vitro microglia enhanced vessel sprouting via 
paracrine mediators as well. Using a chimeric VEGFR-1 molecule, which sequesters VEGF, 
it was shown that the inhibition of VEGF did not alter the sprouting efficiency in the presence 
of microglia. Therefore it was demonstrated that the paracrine effectors are independent of 
VEGF (Rymo et al. 2011).  
 
Macrophages in induced angiogenesis 
 
The involvement of macrophages in tumour angiogenesis was studied in a mouse strain that 
develops mammary cancer and it was observed that the malignancy of a tumour is linked to a 
high density of the vasculature within the tumour, the so-called angiogenic switch (Lin et al. 
2006). This mouse strain was crossed with the mouse strain that has an inactive mutation in 
the CSF-1 gene. Significantly less macrophages infiltrateding tumours and a delayed onset of 
the angiogenic switch were observed. In contrast the overexpression of CSF- 1 in mice 
susceptible to mammary tumours lead to the formation of a dense vasculature before the 
tumours became malignant. Vascular network densities were comparable to that of malignant 
tumours in transgenic mice with a normal expression of CSF-1. Therefore it was concluded 
that infiltrating macrophages play a crucial role in tumour angiogenesis, the angiogenic 
switch and the progression of malignancy (Lin et al. 2006).  
 
Since then tumour-associated macrophages (TAM) have been extensively studied. Many 
reviews exist, which summarise their occurrence, phenotype and mode of action. In human 
tumours it was observed that a high TAM density in the tumour was associated with a poor 
prognosis (Sica et al. 2008) and with an increased microvessel density (Murdoch et al. 2008). 
It is well established that the development into a clinically relevant tumour depends on the 
ability to induce the angiogenic switch, which is supported by the microenvironment. Cells of 
the tumour environment are resident fibroblasts, EC and infiltrating inflammatory cells. 
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Various phenotypes of monocytes and macrophages with various functions in the tumour 
were identified as TAM (Laurent et al. 2011). M1 macrophages, which secreted high levels of 
cytotoxic cytokines like TNF or IL-12 within the tumour, supposedly suppressed tumour 
growth (Murdoch et al. 2008; Sica et al. 2008). On the other hand M2 macrophages promoted 
tumour progression with various pro-angiogenic cytokines like VEGF, IL-8, bFGF and PDGF 
and immune-suppressive cytokines like IL-10 and TGF-β. Further they secreted various 
proteases like the urokinase plasminogen activator (uPA), matrix-metallo protease (MMP)-2, 
-7, -9, -12 and elastase, which digested the ECM thereby promoting endothelial sprouting and 
metastasis (Murdoch et al. 2008; Sica et al. 2008). As macrophages are highly plastic it is 
assumed that the tumour cells and/or tumour environment influence monocytes to polarise 
into a M2 phenotype (Sica et al. 2008). 
 
As even TAMs are a heterogeneous population, it was analysed if specific subpopulations of 
TAMs were responsible for the angiogenic switch (De Palma et al. 2005). Using a tumour 
model in chimeric mice with Tie-2-GFP reconstituted bone marrow it was shown that three 
distinct cell types exist in newly formed tumour vasculature, which expressed the Tie-2 
receptor: EC (CD31+, CD34+), monocytes/macrophages (CD45, CD11b) and mesenchymal 
progenitor cells (MPC) (CD31-, CD45-, CD13+, Sca-1+). MPC were shown to differentiate 
into adipocyte- and osteoblast-like cells. Interestingly, not only MPC but also Tie-2 
expressing macrophages (TEM) were observed in close contact with blood vessels. TEM 
were demonstrated to enhance angiogenesis in various tumour models and were identified to 
express bFGF, a strong angiogenic factor. Although it was assumed that MPC are pericyte-
precursors, neither MPC nor TEM were found to express NG2. However, by tracking of MPC 
after co-injection of MPC subcutaneously with tumour cells, it was observed that MPC give 
rise to mature pericytes, which did not express Tie-2 anymore. The fate of TEM was not 
followed up (De Palma et al. 2005). However, by the perivascular location and the pro-
angiogenic character it is likely that TEM give rise to “early pericytes” (Illustration 2-1). 
Interestingly, macrophages involved in anastomosis during embryonic development also 
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expressed Tie-2 (Fantin et al. 2010). Therefore Tie-2 might be a good indicator for pro-
angiogenic cells, in particular monocyte-derived ones and potentially also a marker for 
pericyte progenitors.  
Monocyte-derived cells in a perivascular location were also observed in situations of 
angiogenesis, besides that in the tumour (Kim et al. 2009). In a sophisticated approach a 
murine model of parabiosis with a common blood circulation between a GFP-transgenic and a 
wild-type mouse was established. Angiogenesis was studied in three different models: a 
wound assay, an implanted gel-foam and a subcutaneous tumour. It was observed that CD31 
and VEGFR-2 were not only expressed by EC as expected, but were also found on 
macrophages, which were identified by the expression of F4/80 and the lack of vWF. CD31, 
VEGFR-2 and F4/80 were also found on circulating monocytes (Kim et al. 2009), indicating 
that this subset of monocytes could give rise to the observed macrophages. It was found in all 
angiogenesis models that blood vessels consisted of EC (CD31+) derived from the wild-type 
mouse with CD31+/F4/80+ macrophages in the perivascular space, derived from the wild-
type and also from the GFP-transgenic mouse. When blood vessels were analysed for 
pericytes by identifying desmin-expressing cells, these were only found in tumours, where 
larger vessel had formed. The desmin-expressing cells in the tumour originated from both the 
wild-type and transgenic mouse and expressed CD31 as well (Kim et al. 2009). As neither 
mature pericytes nor MSC express CD31, this indicates that the emerging pericytes could be 
of monocyte origin, which expressed CD31 and were the main cell type, which infiltrated the 
sides of angiogenesis. However the co-localisation of F4/80 with desmin was not tested. It is 
therefore likely that a subpopulation of TAM and other monocyte-derived cells during wound 
healing represent an “early pericyte” population (Illustration 2-1). 
 
 
Other non-conventional monocyte-derived cells generated in vitro 
 
Monocytes were also isolated from peripheral blood mononuclear cells (PBMC) and cultured 
in vitro to differentiate into cells, which differ from the classical macrophages: 
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Fibrocytes and fibrocyte-like cells 
 
In 1994, Bucala and colleagues observed a large influx of haematopoietic cells into 
subcutaneous wound chambers (Bucala et al. 1994). Interestingly they found an adherent 
spindle-shaped cell population within that stained for collagen I and vimentin, as well as for 
haematopoietic markers CD34. These cells resembled a novel population of circulating cells 
with a fibroblast-like morphology, which they termed fibrocytes (Bucala et al. 1994). By 
culturing of PBMC in FBS supplemented DMEM, they identified a plastic-adherent spindle-
shaped population, which was positive for collagen I, vimentin and fibronectin, as well as for 
markers CD11b, CD34 and CD45, which indicated a haematopoietic origin. As they also 
found CD34 expressing cells within scar tissue, they concluded that besides fibroblasts there 
is another population of fibroblast-like cells named fibrocytes, which is blood-borne and will 
contribute to wound healing and scaring (Bucala et al. 1994). It was noted that although 
collagen I is an ECM protein, only the presence of intracellular collagen was analysed by 
flow cytometry. Therefore collagen secretion and matrix-deposition, which is crucial for 
fibroblasts or fibroblast-like cells that contribute to wound healing or scaring, was not 
confirmed. 
It was identified that although fibrocytes do not express CD14 anymore, they are derived 
from a CD14+ subpopulation of PBMC, which needs contact to T-cells in order to 
differentiate into a fibrocyte phenotype (Abe et al. 2001). It was confirmed that further 
addition of TGF-β1 is able to increase the appearance of fibrocytes and induce the expression 
of α-SMA, which was confirmed by PCR and flow cytometry. Again collagen I expression 
was only showed by flow cytometry and although α-SMA expression was mentioned, the 
presence of α-SMA as fibres, which are necessary for α-SMA to be a functional protein, were 
not shown (Abe et al. 2001). Fibrocytes are potent antigen-presenting cells expressing the 
MHC II complex, which can efficiently stimulate T-cell response (Chesney et al. 1997). 
Interestingly cytokines that are known to induce M2 polarisation in macrophages, IL-4 and 
IL-13 promoted the differentiation into fibrocytes. In contrast, the cytokines IFN-γ and IL-12 
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that are known to induce an M1 phenotype, inhibited the appearance of fibrocytes (Shao et al. 
2008). This indicates that fibrocytes have a M2 phenotype.  
Fibrocytes were studied for their pro-angiogenic abilities and were found to express MMP9, 
VEGF, bFGF, PDGF, IL-8, GM-CSF and angiogenin (Hartlapp et al. 2001). In terms of 
function it was demonstrated that fibrocyte-conditioned media was able to enhance tubular 
network formation of EC on matrigel and enhance blood-vessel formation in an in vivo 
matrigel plug (Hartlapp et al. 2001). Interestingly a similar factor panel was responsible for 
TAM’s induction of angiogenesis (Murdoch et al. 2008; Sica et al. 2008). Further fibrocytes 
were found to home into areas of wound healing, with some fibrocytes localised around 
newly formed blood vessels, when they were injected into the circulation when a full-
thickness skin wound was made (Abe et al. 2001). Although methods currently used to 
characterise fibrocytes as collagen I positive cells are unconventional, these cells could 
represent an in vitro cell population with M2-TAM characteristics and a subpopulation of 
fibrocytes could even be able to give rise to “early pericytes” (Illustration. 2-1).  
Other groups attempted to generate multipotent progenitors from peripheral blood, which 
would differentiate into other lineages. Although the differentiation capacity of these cells is 
disputable, it was suggested that fibrocytes are similar to the monocyte-derived “multipotent” 
cell types, described by other groups (Bellini et al. 2007). 
The Huberman group characterised CD14+ monocytes that evolved in culture under high 
doses of M-CSF and PMA into a subpopulation of fibroblast-shaped, elongated cells, to 
which the authors refer to as f-Φ cells) (Zhao et al. 2003). After treatment with M-CSF and 
IL-6 for five days these cells represent up to 50% of the total population. In contrast to bona 
fide monocytes, these cells loosed MHCII markers and upregulated the markers CD45 and 
CD34 and type I collagen. Using high concentrations of growth factors EGF, NGF, VEGF 
and HGF, f-Φ were induced into cells expressing epithelial, neuronal, endothelial and 
hepatocyte markers. Marker expression was tested by immunocytochemistry. No functional 
tests were performed (Zhao et al. 2003). 
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The Kuwana group has referred to these f-Φ cells as monocyte-derived multipotential cells 
(MOMC) (Kuwana et al. 2003). This group differentiated MOMC from circulating CD14+ 
monocytes. MOMC expressed haematopoietic and monocyte lineage markers, including 
CD45, CD11b and CD14. They also expressed several stem cell markers, such as CD34 and 
CD105, but not CD117/c-kit and CD133. In addition, MOMC were positive for collagens I 
and III, fibronectin, and vimentin, signature proteins of cells of mesenchymal origin. The 
presence of collagen I and III was demonstrated by immunocytochemistry and was only 
intracellular and therefore the secretion of these ECM proteins was not confirmed. The 
Kuwana group obtained these cells in vitro on fibronectin-coated plates in 10% FBS in 
DMEM. The non-adherent cell fraction was removed after 3 days. After 7 to 10 days of 
culture MOMC represented 3-10% of the originally starting number of adherent cells. More 
than 95% of these cells displayed a spindle-shaped phenotype. Interestingly, MOMC 
differentiation occurred only when CD14+ cells were cultured in medium that has been 
conditioned by CD14- cells, and on fibronectin (Kuwana et al. 2003). The necessary presence 
of CD14- cells for the differentiation of CD14+ cells into fibrocytes was also observed by Abe 
et al. (2001). The Kuwana group differentiated MOMC into osteoblast-, adipocyte- 
chondrocyte- and myoblast- like cells (Kuwana et al. 2003). However calcification, which 
was stained by alizarin red, was shown to be intracellular. Therefore a bona fide calcified 
bone matrix, as expected for osteoblasts, could not be confirmed. Chondrocyte differentiation 
was performed in monolayer culture and not as a pellet. It resulted in intracellular expression 
of collagen II, which in order to resemble cartilage has to form a dense ECM. Although 
MOMC induced into adipocytes showed some staining with Oil Redo, no stained lipid 
droplets were evident. Myogenic differentiation was confirmed by immunocytochemical 
staining for myomarkers, however myotube formation was not demonstrated (Kuwana et al. 
2003). Therefore differentiation of MOMC seems to lack the hallmark evidence, which is 
expected for mesenchymal progenitors.  
Similarly to the Huberman group, the Faendrich group used a multistep protocol, employing 
growth factor cocktails, reducing agents and ethanol to obtain cells, which they called 
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programmable cells of monocytic origin (PCMO). They differentiated the PCMO into 
hepatocyte- and pancreatic islet- (Ruhnke et al. 2005) and chondrocyte-like cells (Pufe et al. 
2008). 
Hong et al. (2005 and 2007) was the first group to have in vivo evidence that fibrocytes 
differentiated into adipocyte-like cells and incorporate into fat tissue, expressing the fat-
specific marker leptin (Hong et al. 2005; Hong et al. 2007).  
The demonstrated differentiation potential of fibrocytes into various lineages has to be seen 
critically at this point of time. In many cases differentiation is based on marker expression 
only. Very little functional and in vivo experiments were done. In addition functional 
characterisation of differentiated fibrocytes is not as convincing as with mesenchymal stem 
cells.  
 
Endothelial progenitor cells 
 
EC are found at the interior wall of blood vessels representing a dynamic interface between 
circulating blood and surrounding tissue. As such they have a barrier function and control the 
migration of cells and molecules.  
Generally it is believed that a common progenitor of the haematopoietic stem cell (HSC) and 
the EC exists (Hristov 2003). The progenitor is called haemangioblast and is situated in the 
bone marrow. It gives rise to an early endothelial progenitor cell (EPC), which expresses the 
HSC marker CD133 and CD34 and can already be found in the blood circulation. The early 
EPC matures in the circulation and then first starts to express CD144 (VE-Cadherin) and 
vWF loosing CD133 at the same time and is often referred to as late EPC. The 
haemangioblast does not express any leukocyte (CD45) or monocyte (CD14) marker during 
any stage of maturation. Therefore early EPC are isolated from peripheral blood by CD133 
selection and late EPC are isolated from peripheral blood by CD34 and/or VEGFR-2 
selection. Mobilising EPC from the bm using GM-CSF or VEGF can increase the cell yield at 
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harvest. The first to isolate EPC by markers CD34 and VEGFR-2 were Asahara and collegues 
(Asahara et al. 1997; Hristov 2003). 
 
Endothelial progenitor cells could be also isolated from peripheral blood without cell sorting, 
when PBMC were seeded as a crude cell mixture on fibronectin or collagen I coated plates in 
endothelial medium (Ingram et al. 2004). After two weeks of culture, small colonies with 
cobble-stone morphology emerged. These colonies had high proliferation potential with up to 
thirty population doublings (Ingram et al. 2004) and are often referred to as outgrowth 
endothelial cells (OEC) or late EPC. OEC are derived from the bone marrow and are not 
detached cells from existing blood vessels (Lin et al. 2000). 
 
Interestingly after only one week of culture spindle-shaped cells appeared, which are referred 
to as endothelial like cells (ELC) or early EPCs. In contrast to OEC, they did not express all 
endothelial markers like eNOS (Gulati 2003) or CD146 (Fuchs et al. 2006), but express 
monocyte marker CD14 and did not form tubes on matrigel on their own (Hur 2004; Mukai et 
al. 2008; Fuchs et al. 2006). When co-cultured with EC they co-localised with formed tubes, 
however ELC were only attached to the tube surface and not incorporated into the tube 
structure (Mukai et al. 2008). Early EPC were derived from monocytes and secreted MMP9 
(Yoon 2005). They were shown to have an angiogenic potential, however not by acting like a 
proper EC, but rather by secreting angiogenic factor like VEGF and IL-8 (Hur 2004). Early 
EPC expressed many endothelial markers like CD34, CD31, VEGFR-1 and -2, VE-Cadherin, 
CD105 and vWF (Yoon 2005). Interestingly, early EPC and fibrocytes seem to be very 
similar in terms of morphology and marker expression and are both derived from monocytes 
(Kuwana et al. 2006).  
The co-localisation of ELC with an endothelial network on matrigel indicates a pericytic 
nature, although as shown in Chapter 1 (Fig. 1-6) these characteristics do not allow the 
identification of pericytes.  
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Goals	  and	  objectives	  
 
Angiogenic blood-derived cells would hold a great potential for autologous cell therapy of 
ischemic diseases like critical limb ischemia, myocardial infarction and stroke.  
Autologous cell therapy has many advantages over allogeneic cell therapy (Mason and 
Dunnill 2009). Using the patient’s own cells avoids the risk of immune rejection of the 
transplanted cells and the risk of donor to patient disease transmission. Further the translation 
into a clinical setting is simpler regulated. However the optimism associated with autologous 
cell therapy was greatly diminished due to its drawbacks. Cell harvesting bears risks and 
discomfort for the patient, cell harvest often results in low cell numbers, therefore cells need 
to be expanded ex vivo. Consequently, cell expansion will require time and the treatment will 
be prolonged bearing the potential to miss the therapeutic window. Further cells lose their 
functionality over time in in vitro culture and thereby risking the therapeutic effect of the cells 
(Mason and Dunnill 2009). 
We aimed to overcome current shortcomings of autologous cell therapy. Therefore we 
employed peripheral blood as cell source, as it is easy accessible, the isolation bears minimal 
risks for the patient and blood is drawn on a regular basis during hospitalisation. 
We attempted to generate “early pericytes” (Illustration 2-1) from peripheral blood. We 
employed current protocols described for fibrocytes, MOMC and early EPC as a base to 
develop a protocol, which allows the generation of a large number of these cells. To enhance 
the current protocols we used the biophysical principle of macromolecular crowding, which 
generates an excluded volume effect by introducing carbon-hydrate based macromolecules 
into the cell culture system (Chen et al. 2011).  
The generated cells were characterised by means of marker expression and functional assays 
in vitro and in vivo with particular emphasis on their angiogenic potential and pericytic 
characteristics. Due to the cell type’s marker profile and functional behaviour we called the 




Generation of spindle-shaped cells in large numbers in the presence of macromolecules 
 
It was observed for various cell types that in the presence of a cocktail of macromolecules 
containing Ficoll with the molecular weight of 70 kDa (Fc70) and 400 kDa (Fc400) at 
concentrations of 37.5 mg/ml and 25 mg/ml, respectively, the proliferation of these cells was 
increased and larger number of human bmMSC and fibroblasts could be expanded. As the 
uptake of these macromolecules and their degradation within the cell could be demonstrated, 
it was hypothesised that the Ficoll-cocktail acts as a source of glucose, which is mobilised 
within the cells and allows for a enhanced cell doubling (Rashid et al. in preparation). Ficoll 
is a sucrose polymer, which is added to cell cultures in order to produce a macromolecular 
crowding effect (Chen et al. 2011). This effect is employed to emulate extracellular in vivo 
conditions, which are crowded as well. The macromolecules exclude volume and decrease 
thereby the accessible volume for other components. This has consequences for enzyme 
kinetics and efficiency of enzymes like the Taq-polymerase and BMP-1, thereby having 
downstream effects on matrix deposition and cell differentiation. It is postulated that 
macromolecular crowding enhances protein-protein interactions and molecular assembly as 
well as reduces the entropy and thereby decrease energy barriers for reactions taking place in 
the cell culture. Cell culture is a very complex system, therefore the study of such isolated 
effects is very difficult (Chen et al. 2011).  
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Figure 2-1: PBMC take up ficoll macromolecules of various macromolecular weights 
PBMC were incubated on non-adherent plates with FITC-labelled Fc70 or Fc400 in basal media for 
one hour, collected washed and fixed with formaldehyde. Cell nuclei were stained with DAPI (blue) 
and the cytoskeleton with 594-tagged phalloidin (red), which binds to cellular actin. Cells were 
analysed with an apotome (Zeiss). Cell types were identified by their nuclear morphology. Fc70 was 
observed in granulocytes and monocytes, whereas Fc400 was in addition found also in lymphocytes.  
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Figure 2-2: Granulocytes and lymphocytes are the main fractions of PBMC to take up ficoll 
macromolecules. 
PBMC were incubated on non-adherent plates with FITC-labelled Fc70 or Fc400 in basal media for 
one hour, collected washed and fixed with formaldehyde. FITC-signal in single cells was analysed by 
flow cytometry. Cells incubated in the absence of ficoll macromolecules were used as a negative 
control (grey graphs). Cell types were identified by their difference in cell size (FS) and granularity 
(SS). Fc70 and Fc400 are taken up mainly by granulocytes and monocytes, whereas only a significant 
signal for Fc400 is found in lymphocytes.  
 
When cultured in the presence of FITC-conjugated Fc70 or Fc400 already at a much lower 
concentration of 1 µM, we observed that freshly isolated PBMC were taking up the respective 
macromolecules within the first hour. Their nuclear shape could identify various cell types, as 
granulocytes have a multi-loped nucleus, monocytes have a kidney-shaped nucleus and 
lymphocytes have an eccentric nucleus and a large nucleus-to-cytoplasm ratio. Ficoll 
macromolecules were found in a granular pattern in the perinuclear region in the cytoplasm, 
which was identified by phalloidin staining of the actin filaments (Fig. 2-1). Fc400 could be 
found within all PBMC, whereas lymphocytes, which had taken up Fc70 were hard to find 
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(Fig. 2-1). To estimate the amount of up-taken ficoll macromolecules, PBMC exposed to 
ficoll macromolecules and not-exposed cells were analysed by flow cytometry. Judging from 
the fluorescent intensity ficoll macromolecules were mainly taken up by monocytes and 
granulocytes. Interestingly, Fc70 did not seem to be taken up by most lymphocytes, whereas 
Fc400 was (Fig. 2-2).  
 
Protocols to generate fibrocytes (Bucala et al. 1994; Abe et al. 2001) and MOMC (Kuwana et 
al. 2003) were modified and ficoll macromolecules added, in an attempt to generate larger 
number of spindle-shaped cells. 
PBMCs were cultured in the presence of the ficoll-cocktail on fibronectin-coated dishes. 
Cultures in the absence of the ficoll-cocktail were used as a control. Non-adherent cells were 
removed after one or three days. We found that after one day more adherent cells were 
present, when cultured with ficoll macromolecules in the culture media (Fig. 2-3). After three 
days, first spindle-shaped cells appeared only in cultures containing the ficoll-cocktail. 
During the next two days of culture, cells with a spindle-shaped morphology appeared in all 
cultures. Interestingly, only a proportion of cells cultured in the absence of ficoll 
macromolecules displayed a spindle-shaped morphology, although even then the spindle-
shaped cells appeared shorter compared to those in cultures containing the ficoll-cocktail 




Figure 2-3: Adherent spindle-shaped cells can be generated from PBMC in the presence of ficoll 
macromolecules.  
PBMC were seeded on fibronectin coated-dishes in the presence of a ficoll cocktail (+Fc) or absence (-
MMC) of ficoll macromolecules (MMC). Media was changed after one (D1) or three (D3) days. 
Spindle shaped cells first developed in cultures of PBMC, which had ficoll macromolecules added. 
After 5 days spindle-shaped cells could be observed in all cultures, although the condition +Fc D1 
yielded the highest proportion of spindle-shaped cells. The addition of Fc-cocktail, as well as the 
prolonged exposure of adherent cells to non-adherent cells resulted in an increased amount of adherent 
cells (*p≤0.01, ** p≤0.001). Data are presented as mean values ± standard deviation. 
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In the presence of ficoll macromolecules with media changed one day after seeding of 
PBMC, spindle-shaped cells appeared with a length of around 100µm (Fig. 2-3). Prolonged 
culture of adherent cells with ficoll macromolecules and non-adherent cells for three days 
resulted in a mixed cell population of spindle-shaped and flat round adherent cells. It was 
therefore decided to culture PBMC in the presence of ficoll macromolecules, as these cultures 
resulted always in a formation of spindle-shaped cells, morphologically different than in the 
absence of the ficoll-cocktail. Although a media change after three days of culture resulted in 
large amount of adherent cells, but many of them did not have a spindle-shaped morphology. 
Therefore the generation of spindle-shaped cells for all subsequent experiments was done 
with a media change after one day of initial culture (Fig. 2-3). 
Around 160,000 spindle-shaped cells could be generated with the optimised protocol from 
one million PBMC seeded (Fig. 2-3). Since from one ml of blood 1-2 million PBMC could be 
isolated by gradient centrifugation, we estimated that we could generate 160,000 – 320,000 
spindle-shaped cells per ml of blood (Fig 2-3). From inquires with the blood donation centre 
at the National University Hospital of Singapore we were informed that during usual blood 
donations around 300-400ml of blood is drawn from the donor. Therefore we estimated that 
we are able to generate 64 to 128 million spindle-shaped cells from one blood donation within 
5 days.  
 
Spindle-shaped cells express pericyte markers  
 
We hypothesised that these spindle-shaped cells could resemble an “early pericyte” 
population (Illustration 2-1) and therefore tested the generated cells for established pericyte 
markers. In addition the expression was compared to endothelial cells, as a negative control 
and to placenta-derived pericytes, as a positive control. To confirm which markers are truly 
pericyte specific we also used bmMSCs, which were shown to express some but not all of the 
established pericyte markers (Fig. 1-4).  
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Figure 2-4: BDAC express established pericyte markers. 
BDAC were generated within 5 days and endothelial cells (EC), placenta-derived pericytes (pericytes) 
and bmMSC (MSC) were cultured to confluency. All cell types were methanol-fixed and 
immunostained for pericyte-related markers PDGFR-β, NG2, α-SMA and desmin. BDAC expressed 
three of the four tested markers. They lacked α-SMA, which was also variably expressed in placenta-
derived pericytes. These pictures are representatives for three independent experiments. 
 
The generated spindle-shaped cells, which we called blood-derived angiogenic cells (BDAC), 
showed common expression of pericyte markers PDGFR-β, NG2 and desmin (Fig. 2-4). 
Although the expression of PDGFR-β was weaker in BDAC than in pericytes and bmMSC, 
the staining was clearly positive and EC, which do not express PDGFR-β, had no detectable 
staining. NG2 was confirmed earlier to be more specific for pericytes (Fig. 1-4) and was only 
expressed on BDAC and placenta-derived pericytes (Fig. 2-4), as expected. Again the 
staining was strongest at perinuclear location, although both cell types had a weaker staining 
of the whole cell body as well. The distribution of the staining was similar in both cell types. 
BDAC did not express any detectable levels of α-SMA. Staining was also absent from EC 
and strongest in bmMSC, as expected. Interestingly placenta-derived pericytes showed a 
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variable expression of α-SMA. When placenta-derived pericytes showed a staining for α-
SMA, it was mostly strong and fibrillar (Fig. 2-4). Desmin was proven to be an important 
marker to distinguish pericytes from other mesenchymal cell types like bmMSC and 
fibroblasts (Fig. 1-4). Interestingly, again only BDAC and placenta-derived pericytes showed 
a staining for this marker. Placenta-derived pericytes showed a granular or a stronger fibrillar 
staining of desmin, whereas BDAC had always a fine granular staining of this marker. 
Therefore BDAC showed the expression of most established pericyte markers, especially the 
ones, which we had shown before to be more specific for pericytes (Fig. 2-4). 
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Spindle-shaped cells express markers related to angiogenesis 
 
Assuming that BDAC will play a role in angiogenesis, we tested the generated cells for 
angiogenesis-related markers. Most markers of the tested markers are endothelial cell related.  
 
Figure 2-5: BDAC express angiogenesis-related markers.  
BDAC were generated within 5 days and endothelial cells (EC), placenta-derived pericytes (pericytes) 
and bmMSC (MSC) were cultured to confluency. All cell types were methanol-fixed and 
immunostained for Tie-2, VEGFR-1, CD31 and PM-2K. BDAC expressed all markers. Tie-2 and 
VEGFR-1 expression was shared with endothelial cells and placenta-derived pericytes, but not with 
bmMSC. CD31 was only observed on endothelial cells and BDAC, whereas PM-2K only stained 
positive on BDAC. These pictures are representatives for three independent experiments. 
 
 
It was established earlier that Tie-2 might be a novel marker to distinguish pericytes from 
other mesenchymal cell types (Fig. 1-4). Accordingly, we found Tie-2 to be expressed by 
placenta-derived pericytes, BDAC and EC but not by bmMSC (Fig. 2-5). Interestingly, the 
staining was strongest in BDAC followed by placenta-derived pericytes and then EC. EC had 
a perinuclear staining, whereas BDAC and placenta-derived pericytes stained strongest at 
perinuclear location but also exhibited staining distributed over the whole cell body. The 
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staining for VEGFR-1 had a similar distribution in the cell types. Again EC, BDAC and 
pericytes showed a positive staining, which was absent in bmMSC. The staining was 
perinuclear in EC and placenta-derived pericytes and was strongest expressed in BDAC, 
which showed an even distribution over the whole cell body. Further BDAC expressed 
markers, which were not shared with placenta-derived pericytes. They expressed CD31, 
which was also found on EC, and were also stained by the macrophage-specific PM-2K 
antibody, which was only expressed by BDAC from the cell types tested (Fig. 2-5).  
BDAC express a unique marker profile 
 
 
Figure 2-6: BDAC express a marker profile not shared by other cells.  
BDAC were generated within 5 days, collected and immunostained with FITC- or PE-tagged 
antibodies against mesenchymal stem cell, endothelial and haematopoietic cell markers. Cells were 
fixed with formaldehyde and analysed by flow cytometry. Main populations were gated and analysed 
for various markers. Controls (grey graphs) were BDAC incubated with corresponding FITC- or PE-
tagged isotype controls. BDAC express some but not all mesenchymal, haematopoietic and more 
specifically monocyte/macrophage related markers. Although angiogenesis related markers (VEGFR-





BDAC were analysed for MSC, endothelial cell and haematopoietic markers. They expressed 
only a fraction of MSC-related markers CD29, CD105 and a proportion of BDAC also 
expressed CD166 (Fig. 2-6). Other markers, which are always expressed by MSCs like CD90 
and CD73 were absent from BDAC. Interestingly CD146, used to isolate mature pericytes 
from various tissues (Crisan et al. 2008), was not expressed by BDAC. Although VEGFR-2 
was found on BDAC, other endothelial cell related markers like VE-Cadherin (CD144) and 
CD34 were not expressed. On the other hand BDAC expressed many haematopoietic cell-
related markers like the pan-leukocyte marker CD45, to some extent the monocyte marker 
CD14, the monocyte/macrophage marker CD11b and the M2-related mannose receptor 
CD206. Interestingly, another macrophage-related marker HLA-DR (MHC II complex) was 
not present on BDAC. Hallmark markers for other haematopoietic cells like the dendritic cell 
marker CD83 and the B-cell marker CD19 were absent from BDAC as well. Although BDAC 
did not express CD34 and CD133, which are also present on haematopoietic progenitors, they 
expressed the haematopoietic progenitor marker c-kit (CD117) (Fig. 2-6).  
 
 
BDAC are distinguishable from blood-derived fibrocytes and endothelial progenitors 
 
As other cell types were described to be generated from peripheral blood and had a spindle-
shaped morphology, BDAC were analysed for hallmark markers described for these cells 
namely collagen I as a marker for fibrocytes and MOMC (Bucala et al. 1994, Abe et al. 2001, 




Figure 2-7: BDAC do not express vWF or collagen I.  
BDAC were generated within 5 days and endothelial cells (EC), fetal lung fibroblasts (Fb) and 
placenta-derived pericytes (Pl-Prc) were grown to confluency. a) Cells were methanol-fixed and 
immunostained for vWF. b) The culture media was collected and pepsin-digested, so that only 
collagenous proteins remained in the solution. Same volumes of samples were loaded into a SDS-
PAGE. The gel was silver stained to visualise the present proteins. c) Cells from these samples were 
used to isolate total mRNAs, which were analysed by RT-PCR for specific mRNAs encoding vWF and 
collagen I. These pictures are representatives for three independent experiments. Results are displayed 
as mean values ± standard deviation. 
 
 
As demonstrated, BDAC shared some endothelial cell markers like Tie-2, VEGFR-1, CD31 
and VEGFR-2, although Tie-2 and VEGFR-1 were also expressed by placenta-derived 
pericytes (Fig 2-5 and 2-6). Therefore we tested BDAC for an endothelial cell specific 
marker, which was also described for blood-derived early EC. As expected, EC stained 
strongly for vWF (Fig. 2-7 a). Stained BDAC cultures showed a weaker granular staining, 
which was not localised around the nucleus and therefore was not staining BDAC directly 
(Fig. 2-7 a). The staining rather referred to platelets, which were still present in the culture, as 
indicated by the granular staining of CD31 in between the stained BDAC (Fig. 2-5). 
BDAC expressed markers described for fibrocytes like CD105, CD45 and partially also 
CD14 although they lacked some of the hallmark markers like CD34 and HLA-DR (Bucala et 
al. 1994, Abe et al. 2001, Hartlapp et al. 2001) (Fig. 2-6). To confirm that BDAC are a 
distinct cell type from fibrocytes we tested BDAC for the secretion of collagen I. We used 
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fibroblasts and placenta-derived pericytes as positive controls. All cell-types were incubated 
with culture medium containing ascorbic acid, which allows the secretion of collagen I. 
Media was collected and digested with pepsin, which will digest all non-triple helical protein 
structures. Media samples and collagen I standards, were separated according to their 
molecular weight with SDS-PAGE and all proteins were silver-stained. As expected strong 
collagen I α-bands were detected in both fibroblast and pericyte cultures (Fig. 2-7 b). Even 
some cross-linked collagen I strands could be observed in the β- and γ-bands. In addition 
placenta-derived pericytes showed additional collagen bands not found in fibroblast-
conditioned media. Most importantly no collagen secretion by BDAC could be detected with 
this assay (Fig. 2-7 b). To confirm the absence of fibrocyte and endothelial cell markers RT-
PCR was performed. No significant mRNA levels of collagen I or vWF could be detected in 
BDAC samples, although samples of control cell types showed strong expression for these 




BDAC are not a multipotent cell population 
 
Since other monocyte-derived cell types were suggested to be multipotent and therefore 
differentiate similar to MSC (Zhao et al. 2003, Kuwana et al. 2003, Ruhnke et al. 2005, Pufe 
et al. 2008, Hong et al. 2005 and 2007), we attempted to differentiate BDAC using standard 
MSC protocols.  
When BDAC were induced into osteoblasts or adipocytes most cells died and detached during 
the differentiation process (Fig. 2-8). Remaining cells were stained for Ca2+ deposition by 
alizarin red after osteogenic induction or for lipid droplets with nile red after adipogenic 
induction. Single adherent cells, which survived the differentiation process, mostly did not 
show any sign of differentiation. If a staining could be found osteogenic induced BDAC 
mostly showed intracellular retention of Ca2+, therefore no calcification of the ECM as in the 
bmMSC-induced positive control could be found. Few BDAC, which showed gold-stained 
lipid droplets, were still spindle-shaped and small as compared to the bmMSC-induced 
positive control (Fig. 2-8).  
 
Figure 2-8: BDAC do not differentiate into osteoblasts or adipocytes. 
Generated BDAC and bmMSC were induced into osteoblasts and adipocytes using standard MSC 
protocols. Calcification was stained with alizarin red (red) in osteogenic induced cultures and fat 
droplets were stained with nile red (gold) in adipocyte induced cultures. BmMSC showed a strong 
differentiation into both mesenchymal lineages, whereas BDAC lacked a comparable differentiation 
potential. These pictures are representatives for three independent experiments. 
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BDAC are distinguishable from classical M1 and M2 macrophages in vitro 
 
BDAC were shown to express some monocyte and macrophage markers as stained by PM-2K 
antibody (Fig. 2-5), CD14 and CD11b and M2 related marker mannose receptor 1 (CD206) 
(Fig. 2-6). In addition macrophages implicated in vascular development and during tumour 
angiogenesis were observed to have an M2 phenotype and express pro-angiogenic proteins. 
Therefore we attempted to compare BDAC with M1 and M2 polarised macrophages in order 
to classify the BDAC in accordance to macrophage phenotypes. As macrophages, derived 
from individual blood samples, are highly variable, BDAC and macrophages were derived 
from the same blood sample, polarised and compared in their secretion of M1 and M2 related 
cytokines as well as their expression of M2 related marker CD206. 
BDAC were generated using the established protocol, whereas monocytes were isolated by 
their adherence to plastic and induced into macrophages using M-SCF. BDAC and 
macrophages were polarised into M1 using IFN-γ and LPS and into M2 using IL-4. Secretion 
of TNF-α (M1) and IL-10 (M2) was quantified by ELISA in the culture media, whereas 
adherent cells were methanol-fixed and immunostained for CD206. To determine the cell 
numbers DAPI-stained nuclei were automatically counted.  
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Figure 2-9: BDAC are distinguishable from classical M1 and M2 macrophages and cannot be 
polarised. 
BDAC and macrophages were generated from the same blood samples and optionally polarised into 
M1 or M2. Culture media was collected after 18 hours of incubation and analysed by ELISA for 
secreted TNF-α and IL-10. Adherent cells were methanol fixed and stained with a FITC-tagged 
antibody against CD206. BDAC do not secrete detectable levels of TNF-α and secreted slight amounts 
after M1 polarisation. However levels are always lower than in M1 macrophage controls. M1 polarised 
BDAC also have slightly increased levels for IL-10, however IL-10 levels are lower in all BDAC 
samples than in any of the macrophage samples. A summary of results of three independent 
experiments is displayed as mean values ± standard deviation. Pictures are representatives for three 
independent experiments. 
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Although not only macrophages from various samples were variable, but samples derived 
from one blood sample showed large fluctuations in their secretion of TNF-α and IL-10, a 
trend in their secretion could be observed (Fig. 2-9). Only macrophages polarised into M1 
showed high expression levels of TNF-α, whereas IL-10 was secreted by standard 
macrophages as well as macrophages polarised into M1 and M2. Most cells expressing 
CD206 were found within the M2 polarised samples. BDAC did not secrete any detectable 
levels of TNF-α and lower levels of IL-10 as any of the macrophages. When it was attempted 
to polarise BDAC using the same protocols as for the macrophages, they expressed slight 
levels of TNF-α, but lower than what was observed for M1 polarised macrophages. The IL-10 
levels were always lower than for any of the macrophage samples, but were slightly elevated, 
when BDAC were attempted to be polarised into M1. The polarisation of BDAC into M2 did 
not result in any increase of IL-10 (Fig. 2-9).  
Interestingly, CD206 staining was already strongest in non-polarised BDAC and was not 
changed upon polarisation. However, the morphology of BDAC changed upon polarisation 
from a spindle-shaped cell body to a round one (Fig. 2-9).  
 
 
BDAC co-localise with and stabilise endothelial networks on matrigel. 
 
Once it was established that BDAC expressed marker of pericytes and markers, which 
indicated a role in angiogenesis, BDAC were tested for pericyte-related and pro-angiogenic 
functions in various in vitro assays. It was established before that pericytes co-localise with 
the endothelial tubular network. This behaviour is necessary but not sufficient to identify 
pericytes. It is further necessary to determine if cells collapse the formed network (Fig. 1-5 to 
1-7). BDAC were therefore fluorescently labelled and co-cultured with EC on matrigel. Their 
co-localisation behaviour was observed via life cell imaging. An electronic version of the 
movie is attached to this thesis. 
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Figure 2-10: BDAC co-localise with endothelial tubular network on matrigel.  
Generated BDAC were pre-labelled with green fluorescence and co-cultured with endothelial cells over 
a time course of 24 hours on matrigel at a BDAC to endothelial cell ratio of 1:2. Pictures of fixed 
locations within a well were taken every 30 minutes. Endothelial cells formed a tubular network on 
matrigel and BDAC co-localised early with this network. They moved along the network (red arrows) 
and accumulated at junction points. These pictures are representatives for three independent 
experiments. An electronic version of the movie is attached to this thesis. 
 
Snapshots of the life cell imaging showed that BDAC co-localise early with still forming 
tubules (Fig. 2-10). Once first tube-like structures became evident, which happens as early as 
after 30 minutes of culture, BDAC were already at tubule locations. During the time course of 
24 hours the endothelial tubular network was formed and BDAC were found to either directly 
co-localise with tubular junction points or to co-localise with tubules and to move to junction 
points (Fig. 2-10). In some cases single BDAC changed location from one junction point to 
another, thereby moving along the tubules (Fig. 2-10, red arrows). When seeded on matrigel 









Figure 2-11: BDAC co-localise with junction points of the endothelial tubular network. 
Generated BDAC were pre-labelled with green fluorescence and co-cultured with endothelial cells on 
matrigel. 40x magnification at 4 hours revealed that BDAC co-localised and accumulated at junction 
points of the tubular network formed by endothelial cells (orange arrows). These pictures are 
representatives for three independent experiments. 
 
 
At higher magnification it could be confirmed that BDAC co-localised preferably at junction 
points of the endothelial tubular network. Therefore sometimes an accumulation of BDAC at 
these locations could be observed (Fig 2-11, arrows).  
As it was established before (Fig 1-5 to 1-7) it was necessary but not sufficient to demonstrate 
the co-localisation of cells with the endothelial tubular network on matrigel in order to 
identify pericytes. Further the stability of the network over time is an important criterion. 
Therefore we repeated the experiment on matrigel using poor media, which did not contain 
any growth factors and only 0.5% FBS. Under conditions of poor media effects resulting from 




Figure 2-12: BDAC co-localise with the endothelial tubular network also in poor culture medium. 
Generated BDAC were pre-labelled with green fluorescence and endothelial cells (EC) with red 
fluorescence. Cells were co-cultured on matrigel in LG DMEM containing only 0.5% FBS and no 
growth factors. Similar endothelial tubular networks were formed in all cultures, but disintegrated 
earlier and more in the absence of BDAC. BDAC stayed co-localised with the network through the 




Figure 2-13: BDAC stabilise endothelial tubular network on matrigel 
BDAC and endothelial cells (EC) were co-cultured on matrigel in LG DMEM containing only 0.5% 
FBS and no growth factors. At 16 hours pictures of the middle section of the wells were taken and the 
total tube length in the taken area was quantified using Fiji software. Significantly more tubular 
structures were still present in cultures containing BDAC. Results are displayed as mean values ± 
standard deviation. Representative experiment is displayed in Fig. 2-12. 
 
 
Under conditions of poor culture medium EC still formed a network (Fig. 2-12), however the 
network dissembled earlier and faster compared to full medium conditions with EGM-2. 
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BDAC still co-localised with the tubular network and stayed at network locations, even when 
the network disintegrated (Fig. 2-12). After the network had just formed, no obvious 
differences in the amount of formed tubes was observed, when EC were cultured alone or in 
the presence of BDAC. However, after 16 hours when the network disintegrated to a large 
extent more tubes were found still present in co-cultures (Fig. 2-12). These differences could 




BDAC contribute and enhance endothelial sprouting in vitro 
 
As BDAC contributed to the endothelial network very early in the tube formation process 
(Fig. 2-10), it was hypothesised that BDAC could contribute to early stages of angiogenesis 
and therefore endothelial sprouting. In addition it was confirmed that pericytes co-localised 
with endothelial sprouts in vitro and enhances endothelial sprouting (Fig. 1-8 to 1-11).  
Therefore BDAC were co-cultured with EC to form spheroids, which were then embedded in 
a collagen I gel to sprout. 
 
Figure 2-14: BDAC contribute to endothelial sprouting in vitro.  
BDAC were pre-labelled in green and co-cultured with endothelial cells to form spheroids, which were 
embedded in a collagen I (Col I) gel to sprout. Over a time course of the next 2 days BDAC were 
observed to migrate together with endothelial cells into the sprouts. These pictures are representatives 
for three independent experiments. 
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BDAC incorporated into the spheroids and migrated with the endothelial sprouts during the 
time course of the next 2-3 days (Fig. 2-14). Although initially BDAC were able to form 
spheroids on there own, they often dissembled during the embedding process or shortly after 
(data not shown). Therefore without a stable spheroid, potential sprouting ability of BDAC 
alone could not be tested.  
It was observed that spheroids that contained EC and BDAC developed more and longer 
sprouts. However, as in co-culture often spheroids of different sizes were formed, a direct 
comparison to the sprouting efficiency of spheroids containing only EC was not possible. 
Therefore spheroids with EC alone were formed and embedded inside a collagen I gel. 






Figure 2-15: BDAC enhance endothelial sprouting in vitro. 
Endothelial cell (EC) spheroids were embedded in collagen I gels in the presence of suspended BDAC 
at various cell concentrations. Pictures of BDAC were taken after 3 days and cumulative sprout length 
per spheroid was quantified using Fiji software. BDAC enhanced endothelial sprouting in a cell-dose 
dependent manner, reduced cell debris in the spheroid core and enhanced sprout integrity. These 
pictures are representatives for three independent experiments. Results are displayed as mean values ± 
standard deviation. (**p<0.01, ***p<0.00001 as compared to spheroids alone) 
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BDAC were able to dramatically enhance endothelial sprouting in vitro in a cell-dose 
dependent manner (Fig. 2-15). Controls, which did not contain any BDAC, had many cell 
debris in the core of the spheroid. When BDAC were added to the collagen I gel less debris 
and at higher cell concentrations of 135,000 BDAC per ml no cell debris, were found at the 
core of the spheroid. Interestingly, also the morphology of the endothelial sprouts had 
changed. Endothelial sprouts in controls appeared as loose arrangements of single EC, 
whereas at higher BDAC concentrations sprouts appeared smooth and continuous. Single EC 
could not be recognised within the sprouts (Fig. 2-15).  
 
 
BDAC have a pro-angiogenic secretion profile and actively support endothelial 
sprouting via MMP secretion. 
 
Once established that BDAC stabilise endothelial tubular structures and enhance endothelial 
sprouting manifold, even if not always in direct contact with EC, it was hypothesised that 
BDAC will secrete factors, which are pro-angiogenic and will support EC in these assays. 
Therefore the secretion profile of BDAC was analysed.  
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Figure 2-16: BDAC secrete a proangiogenic marker profile.  
BDAC conditioned media (BDAC-cond) and blank media (blank) as a control were collected and 
analysed using a nitrocellulose membrane with capture antibodies agaist various angiogenesis-related 
proteins (RnD). Captured antigens are visualised chemiluminescently. Dark spots at various locations 
of the membrane represent antigens present in the BDAC conditioned medium. Signal intensity of all 
locations on the membrane were quantified using ImageJ and are plotted on the graph. Positve controls 
(both left and right upper corner) are comparable in BDAC conditioned medium and control, whereas 
the negative control (right lower corner is absent from both). BDAC secreted high levels of pro-
angiogenic proteins, whereas they lacked most anti-angiogenic proteins. These pictures are 
representatives for two independent experiments. 
 
 
BDAC conditioned media or blank media, processed in the same way, was analysed with a 
membrane, which captured various pro- and anti-angiogenic proteins, which then could be 
visualised chemiluminescently. Intensity meassurements of the signals were performed with 
ImageJ. Both left corners and the upper right corner were positive controls of the membrane 
and the signal intensity appeared to be the same on both membranes. The lower right corner 
was the negative control and did not show any staining on either membrane. BDAC showed a 
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strong secretion for various pro-angiogenic factors, the most pronounced ones are CXCL16, 
GM-CSF, HB-EGF, MMP9 and its inhibitor TIMP-1, uPA and its inhibitor PAI-1, IL-8, 
VEGF and MCP-1 (Fig. 2-16). Interestingly BDAC lacked most anti-angiogenic factors like 
Activin A, TGF-β1, IL-1 or Thrombospondin. Only CXCL4 (PF4) was detected in the 
conditioned media (Fig. 2-16).  
Intrigued by the strong pro-angiogenic profile we focused on the secretion of proteases. 
BDAC secreted MMP9 and its inhibitor TIMP-1 as well as the protease uPA and its inhibitor 
PAI-1. This indicated that a balance exists, which allows a fine tuned degradation of 
extracellular matrix proteins. As during sprouting MMPs have to digest the ECM in order for 
the endothelial sprouts to protrude into the tissue, we concluded that BDAC might actively 
supporting EC in this process. Using zymography we analysed secreted MMPs from spheroid 
sprouting assay samples and monolayer culture supernatants.  
 
Figure 2-17: BDAC secrete MMP9, which digests gelatine and collagen I in a zymograph. 
Samples from the spheroid-sprouting assay (Fig. 2-15) as well as gel samples, which contained 
endothelial cells (EC) and BDAC single cell suspensions, as well as supernatants from monolayer 
cultures were analysed. Same volumes were loaded into SDS-PAGE cells, which had either gelatine or 
collagen I co-polymerised. Proteins were separated on the gel accordingly to their weight, MMPs were 
re-natured within the gels and allowed to digest proteins at their respective locations. Samples 
containing BDAC showed main digested bands around 80kDA, whereas samples without BDAC, only 
containing endothelial cells as spheroids or single cells showed main digested bands at 60kDa. Only 
MMPs at 80kDA were able to digest significant bands in a collagen I zymograph. The MMP of action 




The zymographs contained either gelatine or collagen I as proteins, which can be digested by 
MMPs. For the collagen I zymographs the same collagen I was used as in the spheroid 
sprouting assay (Fig. 2-14 and 2-15). Same volumes of samples were loaded into each well of 
the gel. Digested bands at molecular weights of 60 kDa and 80kDa were observed (Fig. 2-17). 
Interestingly main bands at 80kDa were observed only in samples collected, in which BDAC 
were present. Samples, which only contained EC, showed bands mainly at 60 kDa. Digested 
bands at 80kDa increased with the amount of BDAC co-cultured in the spheroid-sprouting 
assay and peaked for the supernatant of BDAC monolayer cultures. Interestingly, the same 
cell number of EC resulted in less digestion of the gelatine zymograph and only a weak 
digestion of the collagen I zymograph. In the collagen I zymograph only samples containing 
BDAC were able to show significantly digested bands (Fig. 2-17). Corresponding to previous 
findings in the secretion profile of BDAC (Fig. 2-16) the MMP at 80kDa was identified as 
MMP9 (Fig. 2-17).  
To test if MMP9 was an important factor responsible for the enhancement of endothelial 
sprouting by BDAC, MMP9 was inhibited using a small synthetic molecule.  
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Figure 2-18: MMP inhibition decreases sprouting efficiency only in EC -BDAC co-cultures. 
Spheroid sprouting assay was repeated with endothelial cells alone (EC) or in co-culture with 
suspended BDAC (+BDAC) within the gel in the presence of a MMP9 inhibitor or only its vehicle 
(DMSO). Cumulative sprout length per spheroid was measured with Fiji software. BDAC enhanced 
sprouting significantly and this effect could be decreased by the addition of the inhibitor. These 
pictures are representatives for three independent experiments. Results are displayed as mean values ± 
standard deviation. (* p ≤ 0.01, ** p ≤ 0.003) 
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As expected the addition of BDAC to endothelial spheroids into the collagen I gel enhanced 
sprouting significantly (Fig. 2-18). The inhibition of MMP9 resulted in a decrease of the 
sprouting efficiency only in endothelial cell BDAC co-cultures. In cultures, which contained 
only EC spheroids, no differences between control cultures with vehicle or the inhibitor was 
observed. Although the MMP9-inhibitor was able to decrease the sprouting efficiency to 
some extend, the sprouting efficiency was higher in inhibited co-cultures as compared to 
endothelial cell controls with the vehicle (Fig. 2-18).  
The core of the endothelial cell spheroids in controls with vehicle and inhibitor contained 
many cell debris and the sprouts in these samples were composed of a loose arrangement of 
EC (Fig. 2-18). When co-cultured with BDAC the spheroid core mostly lacked cell debris 
when in presence of the vehicle. Although the spheroid core in co-cultures appeared denser 
when cultured in the presence of the MMP9-inhibitor, almost no cell debris could be observed 
as well. Sprouts appeared continuous with smooth margins in co-cultures, both in the 
presence of the vehicle and the MMP9-inhibitor (Fig. 2-18).  
 
 
BDAC are pro-angiogenic in vivo 
 
After it was established that BDAC are pro-angiogenic in vitro and evidence for their mode of 
action was found, it was analysed if BDAC will be pro-angiogenic in vivo as well. We 
injected BDAC together with a human glioma cell line, namely U87, into the flanks of nude 
mice (n=3) and observed tumour growth and vessel density within the tumour as compared to 
U87 cells alone. U87 cells alone were injected subcutaneously into the left flank and U87 
cells together with BDAC into the right flank of the nude mice. Solid tumours, which resulted 
from the co-injection of U87 cells with BDAC, grew larger in size, as it was clearly visible 
after 4 weeks and after 5 weeks (Fig. 2-19). When nude mice were sacrificed, solid tumours 
were snap-frozen and cryosectioned. Sections from the middle of the tumours were stained 
for various endothelial cell markers in order to visualise blood vessels. Staining with 
antibodies against CD31 yielded a staining mainly of the microvasculature (Fig. 2-20). 
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Figure 2-19: Solid glioma tumour has a larger size and weight, when co-injected with BDAC.  
U87 cells were injected alone or together with BDAC into the flanks of nude mice (n=3). Tumour 
growth was observed overtime. The mice were sacrificed and tumours were isolated after 4 to 5 weeks. 
Although both tumours had the same length and width, tumours, which developed from the co-
injection of U87 cells and BDAC (U87+BDAC) appeared thicker and had an increase in weight as 
compared to the tumour, which developed from the injection of U87 cells alone (U87 control).  
 
Differently vascularised areas were observed within both control tumours and tumours, which 
resulted from the co-injection of U87 and BDAC (U87 & BDAC). The outer areas of both 
tumours were least vascularised and the vascular density peaked in the core of the tumour 
section. Interestingly, even the outer areas of the U87 and BDAC tumours were stronger 
vascularised then the core region of the U87 control tumour. In general a dramatically 
stronger staining was observed in the U87 &BDAC tumours (Fig. 2-20).  
As CD31 is not very specific for EC and BDAC also expressed CD31 (Fig. 2-5), we used 
antibodies against VE-cadherin (CD144) (Fig. 2-21) to confirm the results, which were 









Figure 2-20 : Co-injection of U87 and BDAC results in more microvasculature.  
Excised tumours were snap frozen and cryosectioned. Middle sections of the tumours were stained for 
endothelial cells and therefore also for the vasculature by antibodies against CD31. Different areas of 
the tumour were observed within one section. The outer areas (left and middle picture) were less 
stained than the core regions (right picture). Still tumours, which resulted from the co-injection of U87 





Figure 2-21: Solid tumours, which result from co-injection of U87 cells with BDAC, possess a 
higher vascular density. 
Excised tumours were snap frozen and cryosectioned. Middle sections of the tumours were stained for 
endothelial cells specific marker VE-cadherin. Different areas of the tumours within one section are 
displayed. The outer areas were less stained than the core regions. Small capillaries could not be picked 
up with this staining at the displayed magnification. The tumour, which resulted from the co-injection 




Staining with antibodies against VE-cadherin resulted in a lower density of staining, as small 
capillaries, which became visible with CD31-antibody, were not picked up with the VE-
cadherin antibody (Fig. 2-21). This might be due to the weak staining the VE-cadherin 
antibody displayed in general. This resulted in a staining of small blood vessels, which had 
the lowest density at the outer areas of the tumour and the highest density in the tumour core 
for both the U87 control tumour and the U87 & BDAC tumour. Again it was observed that 
the vascular density at the outer areas of the U87 & BDAC tumour was already higher than at 
the core region of the U87 control tumour. Therefore VE-cadherin staining was in accordance 
with and confirmed observations with CD31 staining (Fig. 2-21).  
Middle sections of both tumours were stained for vWF to visualise single in-migrated cells as 
well as larger vessels. We observed earlier during antibody testing that the microvasculature 
is not stained with vWF-antibodies (data not shown).  
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Figure 2-22: Only in solid tumours, which resulted from the co-injection of U87 cells with BDAC, 
mature larger vessels were observed.  
Excised tumours were snap frozen and cryosectioned. Middle sections of the tumours were stained for 
infiltrated endothelial cells (blue arrows) and larger blood vessels (white arrows) with an antibody 
against vWF. On the left side low magnification of the tumours are displayed. Only the tumour 
developed from the co-injection of U87 cells with BDAC (U87+BDAC), had larger stained capillaries 
in its centre. Higher magnification pictures confirm these observations.  
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Despite the high background, the staining for vWF had a very particular granular pattern 
around the nucleus and was easy to identify. Therefore infiltrated EC could be identified in 
both tumours (Fig. 2-22, light blue arrows) and were mainly present in the outer areas of the 
tumour. In addition strongly stained larger vessels could be observed in the core region of 
only the U87 & BDAC tumour, although very few smaller vessels, positive for vWF, could be 





BDAC represent a unique monocyte-derived cell population, which has pericyte 
characteristics and can be generated in clinically relevant numbers from peripheral 
blood. 
 
In accordance with what we have observed for other cell types, PBMC took up ficoll 
macromolecules. Further, the addition of the ficoll-cocktail to the crude PBMC culture to 
generate BDAC resulted in larger numbers of spindle-shaped adherent cells. Although the 
course of action of the ficoll-cocktail was not shown specifically in PBMC or monocytes, we 
have found that the uptake of ficoll by MSC or fibroblasts resulted in increased metabolic 
rates and an enhanced proliferation of those cells (Rashid et al., in preparation). Therefore one 
way of action might be the increased proliferation of BDAC in culture.  
We modified protocols, which are used to culture fibrocytes (Bucala et al. 1994; Abe et al. 
2001) or MOMC (Kuwana et al. 2003) by adding the ficoll-cocktail and optimising exposure 
time of adherent cells to the ficoll-cocktail and non-adherent cells. It was mentioned before 
that fibrocytes and MOMC only were formed, when co-cultured with non-adherent cells. 
Paracrine factors secreted by T-cells were demonstrated to be necessary for the development 
(Abe et al. 2001; Kuwana et al. 2003). We have shown before that the ficoll cocktail has an 
excluded volume effect and thereby can enhance various interactions (Chen et al. 2011). The 
observations allowed the assumption that in the case of BDAC-culture the ficoll-cocktail 
could also influence the signalling between CD14+ and CD14- cells and thereby support the 
differentiation of monocytes into BDAC. As BDAC are generated from a crude culture of 
PBMC the effects of ficoll macromolecules are hard to define in such a complex system and 
the exact mode of actions remains to be determined.  
Besides the number of adherent cells, BDAC generated in the presence of ficoll 
macromolecules showed a slightly different morphology, indicating that the presence of ficoll 
macromolecules resulted in a potentially different phenotype.  
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In various clinical trials autologous cells were delivered to patients by infusion or by direct 
delivery to the targeted organs. In these trials either crude cultures of bone marrow derived 
mononuclear cells or PBMC, which contained a higher count of stem cells by G-CSF 
mobilisation, were delivered. Therefore only a proportion of this cell mixture was effective in 
the desired treatment. In the case of myocardial infarction crude mixtures of cells or cells 
selected therefrom were delivered at numbers as little as 1.6 ± 1.2 million CD133 selected 
cells or 78 ± 41 million bone marrow mononuclear cells (Tögel et al. 2007). Other clinical 
trials of cell-based therapy of myocardial infarction used numbers of crude mononuclear cells 
like 16, 28, 78, 213 or even 2460 million cells (Dimmeler et al. 2008). Generated BDAC 
make up around 10-20% of initially seeded PBMC. And numbers of 64 to 128 million 
angiogenicly effective cells can be generated within 5 days. Therefore we believe that with 
our current culture system clinically relevant numbers of functionally relevant cells can be 
generated in a short period of time.  
 
The generated spindle-shaped cells were characterised in great detail in terms of their marker 
expression to find correlations to cell types described so far as well as identify potential 
functions. We established a marker profile in chapter 1, which allows distinguishing pericytes 
from other stromal cell types. Although PDGFR-β is necessary to identify pericytes, as it 
functionally allows the recruitment of these cells (Hellström et al. 2001), it is not sufficient to 
distinguish pericytes from other mesenchymal cell types. The expression of α-SMA on the 
other hand is highly variable in pericytes in vitro and expressed by other mesenchymal cells 
as well. Therefore NG2 and desmin are better candidates to identify pericytes. Interestingly, 
pericytes observed in early angiogenesis, which expressed haematopoietic and often also 
monocytic markers were identified by PDGFR-β and NG2 expression (Rajantie et al. 
2004; Ozerdem 2005; Song et al. 2005; Tigges et al. 2008).  
BDAC expressed all of the tested pericyte markers except for α-SMA. Further BDAC shared 
angiogenesis-related markers with EC and pericytes but not with bmMSC. This allows two 
conclusions. First, Tie-2 and VEGFR-1 could represent markers, which allow to identify 
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cells, which play a role in angiogenesis and second, Tie-2 and VEGFR-1 can be used to 
distinguish pericytes from other stromal cells, as it was suggested for Tie-2 in chapter 1. The 
expression of CD31 links BDAC to previous observations of angiogenic monocytes and 
monocyte-derived cells, which potentially could also give rise to CD31+ desmin+ pericytes 
(Kim et al. 2009). In conclusion, these data strongly suggests that BDAC resemble an “early 
pericyte” population as described in the hypothesis (Illustration 2.1).   
 
An important set of markers was established, which was shared by BDAC and placenta-
derived pericytes, which resemble the “late pericyte” population in the current hypothesis 
(Illustration 2.1). However as already indicated by their differences in origin and role during 
angiogenesis BDAC and pericytes can be clearly distinguished in their marker profile. 
Placenta-derived pericytes were shown to share a marker profile with MSC and thereby to 
lack haematopoietic markers. BDAC on the other hand shared only a proportion of MSC 
markers, but lacked hallmark MSC marker CD90 and CD73. As BDAC are generated on 
fibronectin, the expression of the fibronectin receptor CD29 (integrin β-1) indicates that cells 
might be selected for the expression of this marker. CD105 is not MSC specific but also 
expressed by EC and indeed BDAC share markers with EC like CD105 and VEGFR-1 and -2 
as well as Tie-2 and CD31. However, they lacked other endothelial cell markers like CD34, 
CD146 and the specific endothelial cell marker CD144 (VE-cadherin). This indicates that 
BDAC are not EC but play a role in angiogenesis. The lack of CD146 further distinguishes 
BDAC from other pericytes, which are isolated from various tissues by this marker (Crisan et 
al. 2008).  
On the other hand BDAC expressed various haematopoietic markers like pan-leukocyte 
marker CD45, monocyte markers CD14 and CD11b, M2 related marker CD206, although 
they lacked HLA-DR. The data strongly suggests that BDAC are monocyte derived and have 
M2 characteristics, however might lack some classical macrophage function related to antigen 
presentation. In accordance they did not express dendritic or B-cell markers. If BDAC 
represent a differentiated population or if they are still plastic progenitors cannot be figured 
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out by their marker profile, as they lack haematopoietic and endothelial progenitor marker 
CD34 and CD133, but expressed progenitor marker c-kit (CD117).  
 
In an attempt to compare BDAC with other described monocyte-derived cell types, we found 
that they are clearly distinguishable from fibrocytes, which were defined as CD34+ collagen I+ 
cells (Bucala et al. 1994), markers that BDAC did not express. On the other hand BDAC 
shared markers like CD31 and VEGFR-1 and -2 with early EPC indicating a role in 
angiogenesis, but lacked endothelial hallmark markers CD34, VE-cadherin and vWF, all 
markers described for early EPC (Yoon 2005). Further it was demonstrated that BDAC 
lacked any differentiation potential in contrast to MOMC or any MOMC-related cells 
(Kuwana et al. 2003; Zhao et al. 2003; Ruhnke et al. 2005; Pufe et al. 2008; Hong et al. 
2005; Hong et al. 2007). Therefore BDAC represent a monocyte-derived population clearly 
distinguishable from other published in vitro generated monocyte-derived cell types.  
 
Other monocyte-derived cell types, which play a role in angiogenesis, are M2 macrophages 
like TAM (Murdoch et al. 2008; Sica et al. 2008). In addition Tie-2 was expressed by a 
subpopulation of TAM, which had a perivascular location in tumours (De Palma et al. 
2005), as well as macrophages involved in anastomosis during embryonic development 
(Fantin et al. 2010). As BDAC are monocyte-derived, expressed Tie-2 and M2 marker CD206 
they might be related to these monocyte-derived cell types. To better characterise the M2 
phenotype of BDAC, macrophages, unpolarised and polarised towards M1 and M2, were 
generated from the same blood samples and compared to BDAC. BDAC neither showed the 
cytokine expression expected for an in vitro generated M1 or M2 macrophage phenotype as it 
was suggested before (Mantovani 2006). Given the definition of Mosser and Edwards 
(Mosser et al. 2008) they would still resemble an M2 phenotype, because, due to their lack of 
pro-inflammatory cytokines, they are not M1. However they are clearly distinguishable from 
the immune-modulatory M2, which secretes IL-10. Although monocyte-derived cells are 
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highly plastic and the polarisation of macrophages is reversible, BDAC surprisingly were not 
inducible into M1 or M2, indicating a stable phenotype.  
Although different secretion profile of fibrocytes, early EPC and TAM were described, the 
secretion of MMP9, VEGF and IL-8 was mentioned for all three cell types (Hartlapp et al. 
2001, Yoon 2005, Hur 2004, Murdoch et al. 2008, Sica et al. 2008). These factors were also 
secreted by BDAC. Although BDAC can be distinguished from these cell types, this indicates 
a similar mode of action. 
 
BDAC exhibit a pericytic functional behaviour and are pro-angiogenic in vitro and in 
vivo 
 
We have established before (chapter 1) that pericytes co-localise with endothelial tubular 
networks on matrigel, however this behaviour is not sufficient to identify pericytes in vitro. 
The stability of the network in the co-culture has to be ensured as well. When BDAC were 
tested for pericyte characteristics it was found that they co-localise with the endothelial 
network. Further repetition of this assay under poor media conditions resulted in significant 
stabilisation of the network, therefore further confirming the pericytic and pro-angiogenic 
character of BDAC. We further observed that BDAC migrate along the tubular network and 
accumulate preferably at junction points, indicating a directed and specific interaction with 
EC. The early co-localisation pointed to a potential role of BDAC in earlier stages of 
angiogenesis. Therefore we focused on the role of BDAC in endothelial sprouting, which 
happens at the onset of angiogenesis. Again we observed a specific interaction of BDAC with 
EC, as they did not leave the spheroids like we observed with bmMSCs or fibroblasts (chapter 
1), or remained in the core of the spheroid, but co-migrated attached to the endothelial 
sprouts. Further they supported endothelial sprouting, as indicated by the increased 
cumulative sprout length in the presence of BDAC. They were also able to enhance sprout 
integrity and therefore quality and also supported endothelial cell survival, as the lack of cell 
debris in the co-culture with BDAC suggests. As established in chapter 1, this is a behaviour 
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expected for pericytes, as in our assays only pericytes stayed co-localised with sprouts and 
enhances sprout integrity.  
The difference in size and weight of the tumours, which developed from the subcutaneous 
injection of tumour cells with and without BDAC, already indicated that BDAC induce 
vascularisation, as tumour growth is depending on its vascularisation. These observations 
were confirmed by the staining for various markers of the vasculature. The co-injection of 
tumour cells with BDAC dresulted in a drastic increase in vascular density, and in the 
development of mature larger vessels. Therefore BDAC were proven to be pro-angiogenic in 
vivo as well. With accordance to the pericytic markers the functional behaviour of BDAC 
strongly suggests that BDAC were not only pro-angiogenic but also exhibited a pericytic 
phenotype.  
 
BDAC have a pro-angiogenic secretion profile and actively support endothelial 














Extracellular matrix degradation- endothelial 
sprouting, release of pro-angiogenic matrix fragments 
and matrix-bound growth factors (Sunderkötter et al. 
1994) 
Activin A No 
uPA/PAI-1 TGFβ1 No 
GM-CSF Endothelial cell survival, migration and proliferation 
(Sunderkötter et al. 1994; Hoeben et al. 2004; Li et 





IL-8 PF4 Yes 
Platelet-derived 
(Aidoudi et al. 
2010) 
CXCL16 
HB-EGF Endothelial cell migration and tube formation in vitro 
(Mehta et al. 2007), implicated in tumour growth and 
angiogenesis (Ongusaha 2004; Miyamoto et al. 
2007), recruitment of “late” pericytes (Armulik et al. 
2011) 
MCP-1 Strong monocyte/macrophage attractant, pro-
angiogenic in vivo in a leukocyte-dependent and 
independent manner (Salcedo et al. 2000; Ueno et al. 
2000) 
Table 2-1: Angiogenic functions of the secreted factors by BDAC.  
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Although the categorisation of monocyte-derived cells is more recent, the knowledge that 
they can be pro-angiogenic is well established for many years (Sunderkötter et al. 1994). It 
was also believed at that time that monocyte-derived cells, all summarised as macrophages, 
are not pro-angiogenic by default but require the appropriate stimulation (Sunderkötter et al. 
1994). Macrophages were implicated to be involved in various stages of angiogenesis. At the 
onset of angiogenesis the basement membrane around the existing blood vessel and the local 
ECM needs to be digested, in order for EC to start migrating and sprouting. The degradation 
is done by various proteases like MMPs. Further digestion of ECM proteins can lead to pro-
angiogenic matrix-fragments or to the release of matrix-bound pro-angiogenic growth factors. 
Proteases need also to be strictly regulated, as they can degrade almost all ECM proteins, 
therefore a fine-tuned interplay between proteases and their inhibitors has to be present 
(Sunderkötter et al. 1994). Indeed BDAC expressed MMP9 and its inhibitor TIMP-1, as well 
as uPA and its inhibitor PAI-1, which indicates their contribution to a controlled digestion of 
ECM proteins during endothelial sprouting. Further they secreted a set of growth factors and 
cytokines, which are known to support early stages of angiogenesis. GM-CSF, VEGF and IL-
8 are known to stimulate the migration and proliferation of EC (Sunderkötter et al. 1994). On 
the other hand, GM-CSF was demonstrated to stimulate monocytes to secrete a soluble form 
of the VEGF receptor and thereby sequestering VEGF and inhibiting its signalling and 
therefore being potentially anti-angiogenic (Eubank et al. 2004). What role GM-CSF played 
in the context of a complex co-culture of BDAC with EC and in vivo, remains to be 
determined, but from the results of the functional in vitro assays and in vivo observations it 
can be concluded that it did not significantly inhibit the pro-angiogenic functions of BDAC. 
VEGF is a main effector of angiogenesis and a highly specific mitogen for EC (Hoeben et al. 
2004). Chemokine receptors for IL-8 were demonstrated to be present on EC. IL-8 was able 
to induce tube formation and support survival of EC (Li et al. 2003). CXCL16 is a 
chemoattractant for EC and further enhances their proliferation and tube formation on 
matrigel (Zhuge et al. 2005). HB-EGF on the other hand enhanced endothelial cell migration 
and tube formation in vitro, but did not affect their proliferation (Mehta et al. 2007). It is also 
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assumed to play a role in tumour growth and tumour angiogenesis and was suggested as a 
new target in anti-cancer therapy (Ongusaha 2004; Miyamoto et al. 2007). Further HB-EGF is 
also believed to play a role of recruitment of “late” pericytes (Armulik et al. 2011). MCP-1 
induced chemotaxis of EC and was demonstrated to be pro-angiogenic in vivo. As MCP-1 is a 
strong attractant for macrophages, angiogenic outcome was accompanied by a large 
infiltration of leukocytes. However it was proven in a rat aortic sprouting assay that pro-
angiogenic response is also leukocyte-independent (Salcedo et al. 2000). In the tumour the 
expression of MCP-1 is associated with the accumulation of TAM and down-stream targets of 
MCP-1 were found to be VEGF and HIF-1α (Ueno et al. 2000; Niu et al. 2008). The 
described functions for factors secreted by BDAC are summarised in table 2-1.  
On the other hand BDAC lacked most anti-angiogenic factors like Activin A, TGFβ1, IL-1 
and thrombospondin. Where thrombospondin is known to be anti-angiogenic, the effect of the 
other factors is dose-dependent. However high levels of these factors where shown to inhibit 
endothelial cell migration and proliferation (Sunderkötter et al. 1994). PF4 was the only anti-
angiogenic factor found in the conditioned media from BDAC. PF4 also known as CXCL4 is 
a chemokine produced by magakaryocytes and stored in platelets, from which it is released 
once platelets are activated. It is known to inhibit angiogenesis in vitro and in vivo (Aidoudi 
et al. 2010). As platelets are present in the BDAC culture it is likely that PF4 is derived from 
them. Therefore PF4 would not have any effect once BDAC are collected and reseeded into 
an angiogenic assay or evaluated in vivo.  
The secretion profile of BDAC suggests that BDAC are not only strongly pro-angiogenic, as 
it was also shown in vitro and in vivo, but also that they will play a role in early stages of 
angiogenesis. They secreted factors, which degrade ECM and enhance endothelial cell 
migration and proliferation, therefore support processes of endothelial sprouting. As the 
secretion of protease inhibitors like TIMP potentially could neutralise the protease activity of 
BDAC, we further focused on what role BDAC-secreted proteases would play during 
sprouting. We have shown that MMP9 secretion was restricted to BDAC. Further the 
inhibition of MMP9 in a spheroid sprouting assay resulted in a significant inhibition of 
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endothelial sprouting, proving that MMP9 secreted by BDAC is a main driver of endothelial 
sprouting. It was demonstrated that the sprouting efficiency in EC-BDAC co-cultures in the 
presence of the MMP9 inhibitor was still significantly higher than in EC cultures with the 
vehicle. Further all EC-BDAC co-cultures had a reduced amount of cell debris present 
independent from the presence of the MMP9 inhibitor. This indicates that other BDAC-
secreted factors besides MMP9 will play a role in the enhanced endothelial sprouting and 




Currently we are able to generate large numbers of strongly pro-angiogenic cells from 
peripheral blood. This allows not only the unrestricted study of these cells, but also opens 
avenues to generate clinically relevant numbers of patient-derived, functional cells from an 
easy accessible cell source. Since blood drawing has minimal risks for the patient and using 
patient-specific cells also minimises risks of immune-rejection or disease transmission, this 
method has obvious advantages for the patient. Therefore we conclude that by employing 
BDAC as cells for the treatment of ischemic diseases, current shortcomings in autologous cell 
therapy (Mason and Dunnill 2009) could be overcome.  
BDAC are of haematopoietic origin and are related in their marker expression and functions 
to haematopoietic pericytes and TAM described only in vivo so far. Although further studies 
are needed to confirm the working hypothesis of more than one pericyte population, the 
generated data support the hypothesis. This would have further implications on current 
pericyte- or angiogenesis- focused research. Further BDAC would allow for a more detailed 
study of haematopoietic periytes and TAM in vitro. This was done to some extend in this 
study and our results strongly suggest that BDAC are involved in various stages of 
endothelial sprouting. MMP9 secreted by these cells was shown to be one of the main 
effectors in this early phase of angiogenesis. Although they are monocyte-derived and could 
also classify as a M2 macrophages, they are not as plastic as expected from a macrophage. 
 95 
They cannot be induced to be either pro-inflammatory or immune-suppressive, therefore have 
a specific angiogenic and stable phenotype. This result could point to a very important fact for 





In the beginning of this chapter the hypothesis was introduced that at least two pericyte 
populations exist. The “late” pericyte population came more into focus in the recent years, 
especially after they were identified as mesenchymal stem cells, and were studied to a greater 
extent. This study focused on the potential second pericyte population. The generated data 
support the working hypothesis and indicate that the “early” pericyte population is indeed 
monocyte-derived. However, the current data is not able to prove that point and further 
studies need to be done. In particular the perivascular location of BDAC in vivo still needs to 
be shown.  
A first characterisation of BDAC was done in this work. However many questions still 
remain not answered. To prove that BDAC are a type of macrophage, their ability to 
phagocytise needs to be studied. Further the analysis of macrophage characteristics like T-cell 
stimulation would be of great interest. 
Currently BDAC are derived from a crude culture. Although this has the advantage that the 
cell culture in itself is able to induce the generation of this cell type without addition of 
external growth factors, the whole cell culture is not well defined. The current culture might 
contain several cell populations with different functions. This could have consequences on 
analysis and application of these cells, resulting in the need to purify the cell type with the 
desired function beforehand. A defined culture of a single cell type like the monocytes or a 
specific monocyte population might overcome this limitation and give a better understanding 
on how the cell type evolves. Studies in a greater detail would be possible. 
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The current system also employs macromolecular crowders to generate BDAC. Although 
proven to be difficult in such a complex system as cell culture, the mode of action of ficoll 
macromolecules still needs to be determined. Macromolecular crowding induces an excluded 
volume effect, which will have consequences on protein-protein interaction (Chen et al. 
2011). In the case of BDAC generation the excluded volume effect could enhance growth 
factor and cytokine interaction with their receptors. However this point has still to be proven. 
In addition it was shown that ficoll macromolecules are taken up by various PBMC, 
indicating a mode of action exceeding that of excluding volume in the exterior of the cells. 
Within the cells ficoll could be degraded and act as an additional glucose source as indicated 
for other cell types (Rashid et al. in preparation). In this case ficoll macromolecules would 
have an effect on BDAC proliferation, another factor, which needs to be studied.  
As BDAC are strongly pro-angiogenic and can be generated in large numbers from peripheral 
blood, which is easy accessible, they hold a great potential to be used in autologous cell 
therapy of ischemic diseases. Such diseases include critical limb ischemia, chronic wounds, 
myocardial infarction and stroke. However, currently we only have a proof-of-concept that 
BDAC are pro-angiogenic and their efficiency needs first to be proven in representative pre-
clinical disease animal models. In these disease models cells can be introduced directly in and 
around the damaged tissue area or injected systematically. Injected BDAC would need to 
home into the damaged area, a behaviour, which still needs to be sjown.  
Further BDAC were generated so far only from peripheral blood isolated from healthy 
donors. Therefore it remains to be shown that BDAC can be generated from peripheral blood 
of patient suffering from ischemic diseases, which are often accompanied by other diseases 
like diabetes. The health status of the patient might have an effect on number and 
functionality of BDAC.  
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Materials and Methods 
Cell culture 
 
Placenta-derived pericytes, bmMSCs and HUVEC were cultures as described in chapter 1. 
For in vivo experiments U87-MG human glioma cells were grown in LG DMEM 
supplemented with 10% FBS and 1% P/S.  
 
Generation of blood derived angiogenic cells (BDAC) 
 
After approval was obtained from the IRB office, volunteers were recruited to donate blood 
samples of 50 to 100 ml. Blood was drawn from the arm vein and resuspended in 0.5 M 
EDTA, so that the total concentration of EDTA within the blood sample was 2 mM. 25 ml of 
peripheral blood were diluted with 20 ml PBS containing 2 mM EDTA. PBMC were isolated 
over a ficoll gradient (GE healthcare) using manufacturers protocol. 14 ml of Ficoll-paque 
(1.077 g/ml) were overlaid with 22.5 ml of the diluted blood sample in 50 ml Falcon tubes. 
Samples were centrifuged for 30 minutes at 400 g with a slow acceleration and deceleration 
of the centrifuge. Afterwards cells at the interface of the ficollpaque and the plasma were 
collected and washed twice with PBS with 2mM EDTA. PBMC were counted using a 
haemocytometer. PBMC were suspended in LG DMEM with 10% FBS and 1% P/S 
supplemented with the ficoll cocktail (Fc400 25mg/ml and Fc70 37.5mg/ml) at a 
concentration of 2 million cells per ml of culture media. Cells were seeded on fibronectin-
coated dishes at a volume of 0.25 ml per cm2 and therefore 0.5 million cells per cm2. Dishes 
were coated one day in advance over night using fibronectin isolated from bovine plasma 
(Sigma, cell culture tested with a concentration of 1mg/ml) at a 1:50 dilution in HBSS. Dishes 
were coated using a volume of 0.1 ml per cm2. After one day of culture of PBMC, non-
adherent cells and ficoll-cocktail containing media were removed and fresh LG DMEM, 
containing 10% FBS and 1% P/S, was added. Adherent cells were cultured for further 4 days. 
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Study of the uptake of macromolecules by PBMC 
 
PBMCs were isolated as described above and seeded in LG DMEM (without phenol-red) 
containing either FITC-tagged Fc70 or Fc400 on non-adherent dishes for 1 hour. Afterwards 
cells were collected and fixed in 1% formaldehyde for 15 minutes. Fixed cells were analysed 
either using the Cyan flow cytometer (Dako Cytomation) or resuspended in PBS buffer 
supplemented with 0.5 % FBS for further staining. Cells nuclei were stained with DAPI and 
the cytoskeleton with 594-labelled Phalloidin for 30 minutes. Cells were washed once with 
PBS buffer supplemented with 0.5 % FBS and resuspended in PBS. Cells were then 





Flow cytometry was performed as explained in chapter 1. Antibodies used and not mentioned 
in chapter 1 can be found in table 2-2. 
 
Antigen Cat No. Isotype Volume per 50µL Source 
Control 
CD206 551135 FITC Mouse IgG1, κ 10 µL BD Pharmingen 




BDAC were generated and methanol-fixed on day 5. Immunocytochemistry was performed as 
described in chapter 1. Antibodies used and not mentioned in chapter 1 can be found in table 
2-3. 
Antigen Cat No.  Format Dilution Source 
Primary Antibodies 
VEGFR-1 (Flt-1) ab32152 Rabbit monoclonal 1 :100 Abcam 
CD31 (PECAM-1) M0823 Mouse monoclonal 1:50 Dako Cytomation 
vWF A0082 Rabbit polyclonal antiserum 1:1000 Dako Cytomation 
PM-2K ab58822 Mouse monoclonal 1:1000 Abcam 
CD31 ab28364 Rabbit polyclonal 1:50 Abcam 
VE-cadherin ab33168 Rabbit polyclonal 1:50 Abcam 




Adherent cytometry to assess number of adherent cells after 5 days (count of DAPI 
stained nuclei) 
 
Adherent fluorescent cytometry was based on a montage of 9 sites per well taken by a 
coolSNAP HQ camera attached to a Nikon TE2000 microscope at 2x magnification, covering 
83% of total well area. DAPI fluorescence was accessed with a single Dapi filter [Ex 
350nm/Em 465nm]. The number of stained nuclei was imported into Microsoft Excel, and the 
mean ± SD of the areas was calculated. 
 
Differentiation into adipocytes and osteoblasts 
 




Total RNA was extracted using the RNAeasy single step column spin (Qiagen) following the 
manufacturer’s protocol. Isolated mRNA concentrations were measured using Nanodrop and 
cDNA was synthesised from equal amounts of isolated mRNA using Superscript reverse 
transcriptase II. RT-PCR reactions were performed using following primers: collagen forward 
primer 5’ agccagcagatcgagaacat 3’, reverse primer 5’ cttgtccttggggtcttg 3’; vWF forward 
primer 5’taagtctgaagtagaggtgg 3’, reverse primer 5’ agagcagcaggagcactggt 3’. RT-PCR was 
monitored on a Stratagene real-time PCR instrument (Stratagene) with a PCR master mix 
based on Platinum Taq DNA polymerase (Invitrogen). Data analysis was performed using the 
MxPro software (Stratagene). For each cDNA sample, the Ct value was defined as the cycle 
number at which the fluorescence intensity reached the amplification based-threshold fixed 
by the instrument-software. Relative expression level for collagen I and vWF were calculated 
by normalising the quantified cDNA transcript level (Ct) to that of GAPDH. Fold-change of 
mRNA levels between samples was calculated as 2 Ct1-Ct2.  
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Induction of collagen I secretion and SDS-Page of pepsin digested culture  
 
Collagen secretion into culture media was induced by supplementing the culture media with 
100 mM L-ascorbic acid phosphate (Wako Pure Chemical Industries, Osaka, Japan). After 7 
days culture media were harvested into separate vials, culture medium was digested with 
porcine gastric mucosa pepsin (2500 U/mg; Roche Diagnostics Asia Pacific, Singapore) in a 
final concentration of 100 mg/mL. Samples were incubated at room temperature (RT) for 2h 
with gentle shaking followed by neutralisation with 0.1 N NaOH.  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): Medium and cell 
layer samples were analysed by SDS- PAGE with 5% acrylamide under non-reducing 
conditions. A small format was used (Mini-Protean 3; Bio-Rad Laboratories, Singapore). 
Protein bands were stained with the SilverQuestÔ kit (Invitrogen) according to the 
manufacturer’s protocol. Densitometric analysis of wet gels was performed on the GS-800Ô 
Calibrated Densitometer (Bio-Rad) with Quantity One v4.5.2 analysis software (Bio-Rad).  
 
Life cell labelling 
 
BDAC were labeled using the protocol mentioned in chapter 1.  
 
Tube formation assay on matrigel 
 
Tube formation assay was performed as described in chapter 1. HUVEC were co-cultured 
with BDAC on matrigel at a ratio of 2:1. Quantification of total tube length per taken area 
was done with the Fiji software using the simple neurite tracer plugin.  
 
Spheroid sprouting assay and inhibition of MMP9 
 
Spheroid sprouting assay was performed as described in chapter 1. BDAC were either added 
to EC (HUVEC) to form spheroids at a ratio of 1:2 or as single cells at indicated cell 
concentration to the spheroid suspensions in EGM-2 with 5 µg/ml methylcellulose. For 
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MMP9 inhibition MMP9/13 inhibitor (Santa Cruz, sc-311438, Ill. 2-2) was resuspended in 
DMSO to yield a stock concentration of 20.2 mM. MMP9/13 inhibitor was added at a final 
concentration of 2 µM to the spheroid suspensions in EGM-2 with 5 µg/ml methylcellulose. 
The MMP9/13 inhibitor is a piperazine-based, cell-permeable, and highly potent inhibitor of 
MMP-9 (IC50 = 900 pM) and MMP-13 (IC50 = 900 pM). It was reported to inhibit MMP-1 
and MMP-3 at much higher concentrations (IC50 = 43 nM and 23 nM, respectively) and also 
acted as an inhibitor of MMP-7 (IC50 = 930 nM). Cumulative sprout length was measured 
with the Fiji software.  
 





Zymograph SDS-PAGE gels composed of 10% acrylamide gel containing 1mg/ml gelatin or 
neutralised collagen I and of a stacking gel containing 3% acrylamide. Volumes of 20 µl of 
sample were loaded into each well of the gel and proteins in the samples were separated on 
the gel by SDS-PAGE. Zymographs were washed with buffer containing 2.5% TritonX100, 
50 mM Tris, 5mM CaCl2 and 1µM ZnCl2 that allowed the MMPs, which were separated by 
their size to re-nature, for 1 hour. Afterwards zymographs were rinsed with deionised H2O 
and incubated in a reaction buffer containing 50 mM Tris, 5 mM CaCl2 and 1 µM ZnCl2 at 
37°C with gentle agitation over night. Zymographs were stained with Page Blue using 
manufacturer’s protocol. Briefly zymographs were rinsed with deionised H2O twice, 
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incubated for 1 hour with the staining solution and washed 3 more times with deionised H2O. 
Densitometric analysis of wet gels was performed on the GS-800Ô Calibrated Densitometer 
(Bio-Rad) with the Quantity One v4.5.2 image analysis software (Bio-Rad).  
 
Angiogenesis proteome array 
 
BDAC were incubated with LG DMEM containing 0.5% FBS for 3 days. Media was 
collected and un-conditioned media as a control were filtered through a 0.22 µm pore-size 
filter. Secretion profile of BDAC was established using an angiogenesis proteome array from 
(R&D) (Cat. no. ARY007) following the manufacturers protocol. Captured antigens were 
visualised using a chemiluminescence substrate from Pierce (femto) and a Versadoc (Biorad).  
 
In vivo tumour model 
 
2.5 million U87-MG cells were mixed alone or together with 1 million BDAC in 200 µl of 
L15 media and added to concentrated matrigel at a v/v ratio 1:1. Nude mice were anesthetised 
using isoflurane. Cell suspensions (200 µl containing 5 million U87 and 0.5 million BDAC) 
were injected subcutaneously into the flanks of the mice. U87-MG cells alone were injected 
on the left and U87-MG cells with BDAC on the right. After tumours had reached a critical 
size mice were sacrificed and tumours harvested. Tumours were snap-frozen in liquid 
nitrogen and stored at -80°C. Samples were embedded in OCT medium and cryosectioned at 
a thickness of 8 µm. Cryosections were fixed in ice-cold 100% methanol and air-dried. 
Sections were blocked with 3% BSA in PBS for 1 hour and incubated with rabbit polyclonal 
antibodies against CD31, VE-cadherin or vWF diluted in PBS (table 2-3) for 1.5 hours. Slides 
were washed 3 times with PBS for 10 minutes in coblin jars and then incubated with 
secondary antibodies and DAPI for 30 minutes. 3 washes of the slides with PBS were 
repeated and sections were mounted. Sections were viewed using an epifluorescence 





Obtained values were averaged and are displayed as average value +/- standard deviation. P-
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